15th ANNUAL

WORLD adc SAN DIEGO 2024

November 4-7, 2024

Maximizing the Therapeutic Index of ADCs

Innovating Antibody-Drug Conjugate Design, Accelerating Clinical Development & Streamlining CMC to Progress ADCs to Standard of Care Treatments

140+ Industry-Leading Speakers

1200+ Attendees

340+ Companies

6 Dedicated Tracks of Novel Content

Your World-Class Speaker Faculty Includes:

Ricardo Zwirtes
Executive Director, Global Clinical Lead
Daiichi Sankyo

Puja Sapra
Senior Vice President, Biologics Engineering & Oncology Targeted Discovery, Oncology R&D
AstraZeneca

Scott Peterson
Head, ADC Discovery & Cancer Immunology
Pfizer

Zhu Chen
Senior Vice President & Head, ADC Center of Excellence
Genmab

Timothy Lowinger
Chief Scientific & Technology Officer
Mersana Therapeutics

Radhika Balasubramani
Director, Technical Product Steward, Antibody Drug Conjugates
Merck & Co

Mary Jane Hinrichs
Senior Vice President, Global Head of Early Development
Ipsen

Ahsan Arozullah
Senior Vice President & Head of Oncology Development
Astellas

Bilal Piperdi
Vice President, Clinical Development Oncology
Gilead Sciences

Lead Partner: BSP PHARMACEUTICALS

Senior Partners: Ajinomoto · BIO-PHARMA SERVICES · AMBRX · Johnson & Johnson · MilliporeSigma · NJ BIO · Singzyme · TUBULIS · XDC The Bioconjugation Leader

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW

Welcome to the World's Longest Standing & Definitive ADC Forum

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector.

Fueled by Enhertu's tumor-agnostic accelerated approval, practice changing combination results from Seagen and Astellas' PADCEV, a frenzy of companies entering the field, and rampant billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond; **ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking**.

Returning as the world-leading, largest, and most comprehensive ADC focused conference, the **15th World ADC San Diego** will unite over 1,200 industry enthusiasts to **explore end-to-end insights and help you maximize the therapeutic index of your ADCs**.

This event offers an unforgettable experience for everyone working with ADCs, from field novices to long-lasting KOLs. Built with the industry's specific needs in mind, this year's agenda has been reinvigorated with new content from 140+ leading speakers including **Daiichi Sankyo**, **Pfizer**, **AbbVie**, **Merck**, **AstraZeneca**, **Gilead Sciences**, and **ADC Therapeutics**.

Across the 4-day program, learn and discover innovations in linker-payload design, assess novel targets, accelerate preclinical and clinical development whilst overcoming associated toxicity challenges. You'll also be able to benchmark best approaches in combination strategies, and enhance analytical and process development to ensure product quality and optimize CMC strategy.

There is no therapeutic modality generating as much excitement as ADCs, and no conference demonstrates their potential like *World ADC San Diego*. As THE annual touchpoint for the scientific community, don't miss your premier forum to receive unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market trends.

We look forward to welcoming the ADC community back to San Diego this November for a melting pot of innovation, collaboration, and inspiration to **progress ADC development to new standard of care treatments in oncology and beyond**.

The World ADC Team

Your Roadmap to ADC Success From Bench to Bedside:

Discovery Chemistry

Uncover cutting-edge developments in ADC payloads, linkers, and site-specific conjugation technologies to ride the tidal wave of ADC design and chemistry innovation with **Heidelberg Pharma**, **Sutro Biopharma**, and **ADC Therapeutics**

Cellular Biology

Discover novel ADC target discovery and validation, harness biology and omics tools, and efficiently engineer antibody properties to elevate your ADC development for novel target and therapeutic applications with **Bolt BioTherapeutics**, **Oxford BioTherapeutics**, and **SOTIO Biotech**

Translation

Evaluate best in class preclinical development, ADC safety and efficacy characterization, and preclinical model selection and predictiveness to minimize the translational mismatch and supercharge successful ADC progression into the clinic with **Daiichi Sankyo**, **AstraZeneca**, and **Genentech**

Clinical Lessons

Deep-dive into **brand-new early and late-stage clinical data**, contextualize clinical performance, and explore ADC dose escalation to best categorize what makes a clinically effective ADC with **AbbVie**, **Ipsen**, and **Mythic Therapeutics**

Process & Analytical Development

Explore case studies of analytical investigation of complex ADC molecules, DAR and impurity characterization, and learn to streamline drug-linker and conjugation process optimization to reinvigorate your ADC product quality with **Mersana Therapeutics**, **Bristol Myers Squibb**, and **GSK**

Manufacturing & Supply Chain

Understand best practices in handling ADC manufacturing risk and scale up, selection criteria for CDMO partners, ensuring smooth supply chain, and regulatory CMC strategy to best equip you with robust and efficient manufacturing practices under accelerated ADC development timelines with **Exelixis**, **Merck**, and **Pfizer**

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW

ADCs Show Clinical & Commercial Success



*This data is provided by Beacon Targeted Therapies and is correct as of April 2024

Top Talks Not to Be Missed:

TROP2 ADC Development: Exploring the Datopotamab Deruxtecan Mechanism, Clinical Efficacy, & Future Directions

Ricardo Zwirtes, Executive Director, Global Clinical Lead, **Daiichi Sankyo**

Reflecting On Phase I Termination of DHES0815A: What Were the Core Lessons Learned?

Gail Lewis, Senior Principal Scientist, **Genentech**

Breaking Down the Success From the PADCEV-Keytruda Combination & Applying Learnings to Future ADC-Immunotherapy Combinations

Ahsan Arozullah, Senior Vice President, Head of Oncology Development, **Astellas**

Improving Predictability - Deciding on the Best *In Vivo* Model in Order to Replicate Toxicities Clinically

Scott Collins, Director, Non-Clinical Development, **Mersana Therapeutics**

Assessing Drug-Linker Manufacturing & Supply to Ensure Upfront Development Under Accelerated IND Timelines

Candice Wong, Senior Director, Engineering & External Process Development, **Pfizer**

What's New for 2024?

Introducing the Pharmacology Seminar Day Stream

Underpinned by the recent FDA guidance on designing clinical pharmacology studies for ADCs, this brand-new seminar day is designed for ADC experts working in PK/PD and clinical pharmacology. Led by leaders from **Novartis**, **SOTIO Biotech**, **ADC Therapeutics**, **Pfizer** and **Gilead Sciences**, explore ADC pharmacodynamic markers and modeling, early clinical dose optimization and best practices for ADC pharmacology strategy to inform successful ADC clinical performance

Novel Biopharma Speakers

With the largest speaker faculty to date and over 85 new speakers on the program, learn from first-time presenting biotechs **ABL Bio**, **Angiex**, **Huadong Medicine**, **Multitude Therapeutics**, **Mythic Therapeutics**, and **Oxford Biotherapeutics**; as well as oncology leaders from new big pharma on the scene, **Pfizer** and **Ipsen**. They will deliver end-to-end content and insights spanning Degrader Antibody Conjugates, Bispecific ADCs, ADC target discovery, early clinical dosing, managing supply chain ahead of IND submission, and weighing up internal vs. outsourced manufacturing

Exclusive Panel Session: Diversity & Inclusion in Oncology & ADC Clinical Trials*

Ensuring D&I and patient centricity in clinical trials is crucial to encompass the broad range of lived experiences and diverse populations so that all patients can benefit from ADC clinical advances. Led by D&I experts and patient advocates from **Merck & Co**, **Equity Bridge** and **TOUCH, The Black Breast Cancer Alliance**, attend this panel session to explore the significance of D&I in ADC development, understand the patient perspective, and hear successful case studies of implementing patient considerations in clinical trial design and recruitment

*Free to attend with all registration passes

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW

Agenda at a Glance

15th ANNUAL WORLD adc SAN DIEGO 2024

Seminar Day
Monday, November 4

- Introduction to ADCs Day
- 2nd Novel Targeting Moiety & Payloads Day
- 5th Toxicity Day
- 2nd Biomarker & Patient Selection Day
- 8th ADCs in Combination Day (NEW)
- 1st Pharmacology Day
- 3rd Bioanalytical & Process Analytical Day
- 6th CMC Day

Lunch & Networking

- Introduction to ADCs Day
- 2nd Novel Targeting Moiety & Payloads Day
- 5th Toxicity Day
- 2nd Biomarker & Patient Selection Day
- 8th ADCs in Combination Day (NEW)
- 1st Pharmacology Day
- 3rd Bioanalytical & Process Analytical Day
- 6th CMC Day

Diversity & Inclusion in Oncology & ADC Clinical Trials Panel Session (NEW)

Evening Ambassador's Reception

Scientific Program Day One
Tuesday, November 5

Moving the Needle Forward in 2024 & Beyond: What's are the Next ADCs to Re-Shape the Field?

Morning Break & Networking

- Discovery Chemistry
- Cellular Biology
- Translational
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Lunch & Networking

- Discovery Chemistry
- Cellular Biology
- Translational
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Afternoon Break & Technology Slam

What Makes a Clinically Effective ADC? Breaking Down Ongoing ADC Clinical Performance

Scientific Poster Session & Drinks Reception

Scientific Program Day Two
Wednesday, November 6

Showcasing Cutting-Edge Successes of ADC Combinations Reshaping Frontline Treatments in Oncology

Morning Break & Networking

- Discovery Chemistry
- Cellular Biology
- Translational
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Lunch & Networking

- Discovery Chemistry
- Cellular Biology
- Translational
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Afternoon Break & Networking

BCMA Breakdown: Exploring Case Studies of ADC Development for Targets Without an Approved Therapy

11th Annual World ADC Awards

Workshop Day
Thursday, November 7

- **Workshop A** - ADC Chemistry & Properties
- **Workshop B** – Maximizing ADC Translation
- **Workshop C** – Immune Stimulating ADCs
- **Workshop D** – ADC Design Strategy
- **Workshop E** – Impurity Analytics & Control

Lunch & Networking (PICK ANY TWO)

- **Workshop F** – Linker Chemistry 101
- **Workshop G** – Clinical Therapeutic Window
- **Workshop H** – ADC Analytical Toolbox
- **Workshop I** – ADC Computational Design
- **Workshop J** – Regulatory CMC Strategy

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW

Map Out Your World ADC Journey!

With over **120 hours of scientific content** to choose from, navigating your World ADC experience can involve some difficult decisions. Therefore, we have mapped out all the different journeys you can take at the *15th World ADC San Diego* so that you and your team can plan your experience to complement each other, find the best content based on individual expertise, and make sure you aren't missing any important sessions!

Pre-Conference Seminar Day

Monday, November 4

Stay up to date with the innovation in the field through case study presentations and informative discussions led by forward thinking ADC experts

- Introduction to ADCs Day
- 2nd Novel Targeting Moiety & Novel Payloads Day
- 5th Toxicity Day
- 2nd Biomarker & Patient Selection Day
- 8th ADCs in Combination Day
- 1st Pharmacology Day (NEW)
- 3rd Bioanalytical & Process Analytical Day
- 6th CMC Day

ADC D&I Panel Session (NEW)

Evening Ambassador's Reception
Hosted by Abzena

Scientific Program Day One

Tuesday, November 5

- Discovery Chemistry
- Cellular Biology
- Translational
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Poster Session

Drinks Reception
Hosted by AsymBio

Technology Slam

Scientific Program Day Two

Wednesday, November 6

11th World ADC Awards

Post-Conference Workshop Day

Thursday, November 7

Bring your own ADC development challenges to these extended, collaborative sessions aimed to stimulate conversation, discussion, and debate

Workshops for Beginners

- **Workshop A:** ADC Chemistry & Properties
- **Workshop B:** Maximizing ADC Translation
- **Workshop C:** Immune-Stimulating ADCs
- **Workshop F:** Linker Chemistry 101
- **Workshop G:** Clinical Therapeutic Window
- **Workshop H:** ADC Analytical Toolbox

Workshops for Everyone

PICK YOUR TOP TWO SESSIONS

- **Workshop D:** ADC Design Strategy
- **Workshop E:** Impurity Analytics & Control
- **Workshop I:** ADC Computational Design
- **Workshop J:** Regulatory CMC Strategy

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW

Your 2024 Speaker Faculty

Hua Fang
Scientific Director, Clinical Development Oncology
AbbVie



Linjie Han
Associate Director, Analytical Development, Operations S&T, Biologics
AbbVie

Sarah Kiehna
Director, Analytical Development & Quality Control
AbbVie

Laura Kreckler
Senior Principal Research Scientist
AbbVie

Xiaoli Liao
Principal Scientist II, Operations S&T
AbbVie

Laurie Mlinar
Principal Research Scientist II
AbbVie

Hetal Sarvaiya
Director, QTAS (DMPK-BA)
AbbVie

Vikram Shenoy
Senior Scientist I, QTAS (DMPK-BA)
AbbVie

Alireza Tafazzol
Senior Scientist II, Oncology Bioinformatics
AbbVie

Paul Thomas
Principal Research Scientist II, Biologics Analytical Research & Development
AbbVie

Jinwon Jung
Senior Director, Protein Engineering
ABL Bio

Sang Jeon Chung
Chief Scientific Officer
AbTis

Francisco Velasquez
Senior Director, Chemistry
Abzena

Stephen Verespy
Scientific Leader
Abzena

Sonny Hsiao
Founder & Chief Executive Officer
Acepodia

Patrick Van Berkel
Chief Scientific Officer
ADC Therapeutics

Esohe Idusogie
Head, Process Quality & CMC Analytical
ADC Therapeutics

Paul Wolstenholme-Hogg
Vice President, Medicinal Chemistry
ADC Therapeutics

Tomohiro Fujii
ADC researcher
Ajinomoto Biopharma Services

Mike Schmidt
Chief Scientific Officer
Alloy Therapeutics

Shawn Zhang
Chief Scientific Officer
Ambrx, a Johnson & Johnson Company

Seb Caille
Scientific Director, Process Development
Amgen

Paul Jaminet
Chief Executive Officer
Angiex

Ahsan Arozullah
Senior Vice President & Head, Oncology Development
Astellas

CONTENTS

Your 2024 Speaker Faculty

Frank Comer
Director, Tumor Targeted Delivery, Early Oncology Discovery
AstraZeneca

Jay Harper
Director, Early Oncology
AstraZeneca

Lara McGrath
Senior Director, Translational Medicine
AstraZeneca

Jay Mettetal
Senior Director, Oncology Bioscience
AstraZeneca

Puja Sapra
Senior Vice President, Biologics Engineering & Oncology Targeted Discovery, Oncology R&D
AstraZeneca

Dawn Spiller
Senior Director & Group Manager
AstraZeneca

Nicole Swope
Senior Scientist, Analytical Sciences
AstraZeneca

Christina Vasalou
Director, Head of ADC Translational PKPD
AstraZeneca

Weibin Chen
Head of Analytical Chemistry
AsymBio

Wei Gong
CMC Operation General Manager
Aton Biotech

Jenny Hunt
Director, Corporate Alliances
Aureka Biotechnologies

Bertrand Cottineau
R&D Group Head
Axplora

Melanie Derde
Head, Bioconjugation Operations
Axplora

Jake Morris
Senior Account Manager & ADC Insights Lead
Beacon

Shailee Patel
Scientific Liaison Analyst
Beacon

Eleni Taoula
Account Manager
Beacon

L. Nathan Tumey
Associate Professor
Binghampton University

Jian Chen
Director, Translational Research & Preclinical Development
BioAtla

Gerhard Frey
Vice President, Technology Development
BioAtla

Rakesh Dixit
President & Chief Executive Officer
Bionavigen Oncology

Shelley Ackerman
Senior Director & Program Team Lead
Bolt Biotherapeutics

David Bramhill
President & Founder
Bramhill Biological Consulting

Yuan Ren
Principal Scientist, Chemical Process Development, Analytical Chemistry
Bristol Myers Squibb

Sayumi Yamazoe
Associate Director
Bristol Myers Squibb

REGISTER NOW

Your 2024 Speaker Faculty

Maria Elena Guadagno
Technical Operations & Business Executive Director
BSP Pharmceuticals

Stepan Chuprakov
Director of Chemistry
Catalent Pharma Solutions

Marco Lobba
Co-founder & Chief Executive Officer
Catena Bio

Chung-Yi Wu
Chief Executive Officer
CHO Pharma

Mo Xu
Chief Medical Officer
Coherent Pharma

John Woodgate
Senior Strategy Manager, Bioprocess
Cytiva

Caleb Lee
Executive Director
Daiichi Sankyo

Shotaro Nagase
Researcher
Daiichi Sankyo



Ling He
Senior Director, Clinical Bioanalysis
Daiichi Sankyo

Ricardo Zwirtes
Executive Director, Global Clinical Lead
Daiichi Sankyo

Charles Morgan
Head, Regulatory CMC
Denali Therapeutics

Yang Qiu
Chief Scientific Officer
Duality Biologics



Yan Zhang
Senior Director, Translational Sciences
Eisai

Adalynn Harris
President & Chief Executive Officer
Equity Bridge

Engin Ayturk
Senior Director, CMC Bioconjugation, Process Development & Manufacturing
Exelixis

Weijun Li
Senior Director, Biologics Analytical Development & CMC Team Lead
Exelixis

Karina Zuck
Senior CMC Reviewer
FDA

Nicolas Agard
Senior Principal Scientist
Genentech

Gail Lewis
Senior Principal Scientist
Genentech

Paul Song
Chief Scientific Officer
GeneQuantum Healthcare

Yajun Sun
Executive Director, Non-Clinical
GeneQuantum Healthcare

Zhu Chen
Senior Vice President & Head, ADC Center of Excellence
Genmab

Edward Kavalerchik
Senior Medical Director
Genmab



Heller Chen
Senior Clinical Pharmacologist II
Gilead Sciences

Your 2024 Speaker Faculty



Bowen Jiang
Senior Research Scientist I, Bio Formulation & Process Development
Gilead Sciences

Simon Letarte
Director, Extended Structural Characterization
Gilead Sciences

Bilal Piperdi
Vice President, Clinical Development Oncology
Gilead Sciences

Pralay Mukhopadhyay
Vice President, Medicine Development Leader, Oncology R&D
GSK

Mimi Zhu
Senior Manager, Downstream Process Development & Operations
GSK

Juhani Saarinen
Chief Executive Officer
Glykos Finland Oy

Andreas Pahl
Chief Executive Officer
Heidelberg Pharma

Torsten Hechler
Senior Vice President, ADC Research
Heidelberg Pharma

Anikó Pálfi
Director, Biochemistry & Cell Biology
Heidelberg Pharma

Dongzhou Jeffrey Liu
Chief Scientific Officer
Huadong Medicine

Jutta Deckert
Vice President, Research & Development
Iksuda Therapeutics

Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics

Patrick Zweidler-McKay
Former Executive Medical Director
ImmunoGen

Kaijie He
Vice President, Cancer Biology & ADC
Innovent Biologics

Yosup Rew
Chief Technology Officer
IntoCell

Zaiqi Wang
Chief Executive Officer
InxMed

Mary Jane Hinrichs
Senior Vice President, Global Head of Early Development
Ipsen

Jon Travers
Senior Director, External Innovation & Early Development
Ipsen

Dowdy Jackson
Chief Executive Officer
Jackson Consulting Group

Simon Jiang
Vice President, Biology
Lide Biotech

Stephen Slocum
Director, Drug Development, Project Lead
LigaChem Biosciences

Pierre Landais
Director, Commercial Development, Drug Product Services
Lonza

Wei Han Tan
Manager, Technical Sales & Customer Proposals, Drug Product Services
Lonza

Hanna Wagner
Supervisor, Process Development Bioconjugates
Lonza

Your 2024 Speaker Faculty

Hema Balachandra
Associate Director, Biologics CMC
Merck & Co

Radhika Balasubramani
Director, Technical Product Steward, ADCs
Merck & Co

Petra Bennington
Director, Analytical Research & Development
Merck & Co

Llorente Bonaga
Senior Director, Global Regulatory Affairs & Clinical Safety, CMC
Merck & Co

Mary Elmer
Executive Director, Patient Engagement Oncology
Merck & Co

Philip Kuhl
Distinguished Scientist, Bioconjugation & Chemistry Commercialization
Merck & Co

Harshil Renawala
Senior Scientist, Sterile Drug Product Commercialization
Merck & Co

Zhengqi Zhang
Senior Scientist
Merck & Co

Scott Collins
Director, Non-Clinical Development
Mersana Therapeutics

Yuanyuan Li
Director
Mersana Therapeutics

Timothy Lowinger
Chief Scientific & Technology Officer
Mersana Therapeutics

Gary Conway
Principal Production Scientist, GMP Manufacturing
MilliporeSigma

Lisa McDermott
Director, Process & Analytical Development
MilliporeSigma

Yomadis Ortiz
Manager, Process & Analytical Development
MilliporeSigma

John Stevens
Application Specialist, Small Molecules & ADCs
MilliporeSigma

Paul Davis
President
Montgomery Holdings

Xiaona Jing
Senior Vice President, Global Product Development & Partnering
Multitude Therapeutics

Shu-Hui Liu
Chief Scientific Officer
Multitude Therapeutics

Gilles Gallant
Chief Development Officer
Mythic Therapeutics

Vikki Cerniglia
Senior Director, Biopharma Partnerships
Natera

Barbara Valsasina
ADC Portfolio Head
Nerviano Medical Sciences

Naresh Jain
Chief Executive Officer
NJ Bio

Julien Dugal-Tessier
President & Chief Scientific Officer
NJ Bio

Musheng Bao
Vice President, Head of Biology
Nona Biosciences

Your 2024 Speaker Faculty

Nicholas Willumsen
Director & Head, Oncology
Nordic Bioscience

Eshita Khera
Principal Scientist II
Novartis

Jason Reeves
Director, Application Science
Nucleai

David Huang
Director, Medicinal Chemistry
OBI Pharma

Eric Vajda
Vice President, Preclinical R&D
OmniAb

Joanne Lim
Associate Director, Immunology
Orum Therapeutics

Teresa Mako
Scientist I, Medicinal Chemistry
Orum Therapeutics

James Palacino
Head, Research
Orum Therapeutics

Harald Haeske
Chief Medical Officer
Oxford BioTherapeutics

Yu-Tzu Tai
Associate Director, ADC & Translational Research
Oxford BioTherapeutics

Charley Wu
Managing Director
Panlabs Biologics

Amit Garg
Executive Director, Clinical Pharmacology Oncology
Pfizer

Kevin Hamblett
Senior Director, ADC Biology
Pfizer

Yuting Huang
Senior Principal Scientist & Group Leader
Pfizer

Forgivemore Magunda
Principal Pathologist
Pfizer

Scott Peterson
Head, ADC Discovery & Cancer Immunology
Pfizer

Jeffrey Settleman
Senior Vice President, Chief Scientific Officer, Oncology R&D
Pfizer

Flavia Storelli
Clinical Pharmacologist, Oncology Division
Pfizer

Srinath Thirumalairajan
Director, Process Engineering
Pfizer

Candice Wong
Senior Director, Engineering & External Process Development
Pfizer

Conor Barry
Associate Vice President, Global Biologics Technical Lead
Piramal Pharma Solutions

Jun Hayashi
President
Precision Antibody

Vitor Sousa
Director, Business Development
Proveo

John Vieceli
Chief Product Officer
Quantum-Si

Your 2024 Speaker Faculty

John Lambert
Independent Consultant & Honorary Professor
Queens University Belfast

Thomas Nittoli
Senior Director
Regeneron

Allan Ader
Managing Director
SafeBridge Consultants

Joseph Jeong
Vice President, ADC Development Team
Samsung Biologics

Paul Marks
Product Specialist, TFF
Sartorius

Haichuan Liu
Manager, Strategic Marketing, Protein Characterization
SCIEX

Travis Biechele
Vice President, Research
Shasqi

Jose Mejia Oneto
Founder & Chief Executive Officer
Shasqi

Abbas El Sahili
Chief Executive Officer
Singzyme

Tracy Matray
Senior Director, R&D
Sony Biotechnology, a Second-Generation Subsidiary of Sony Corporation

Do-Hyun Nam
Professor, Department of Neurosurgery
Sungkyunkwan University School of Medicine

Martin Steegmaier
Chief Scientific Officer
SOTIO Biotech

Krishna Bajjuri
Senior Director, Chemistry
Sutro Biopharma

Dan Calarese
Director, Innovation & Strategy
Sutro Biopharma

Hans-Peter Gerber
Chief Scientific Officer
Sutro Biopharma

Alice Yam
Vice President, Drug Discovery
Sutro Biopharma

Gang Yin
Vice President, Research
Sutro Biopharma

Anette Sommer
Head of Biochemistry
Synaffix



Hsing-Mao Chu
Chief Executive Officer
T-E Meds

Tim Hagerty
Vice President, Life Science Strategy
Tempus

Richard Klinghoffer
Senior Vice President, Head of Systems Biology
Tempus

Christian Marsolais
Senior Vice President & Chief Medical Officer
Theratechnologies

Ricki Fairley
Chief Executive Officer & Co-Founder
Touch, The Black Breast Cancer Alliance

Dominik Schumacher
Chief Executive Officer
Tubulis

Your 2024 Speaker Faculty

Martina McDermott
Adjunct Assistant Professor
UCLA

Greg Thurber
Associate Professor & Chair, Graduate Education
University of Michigan

Labros Meimetis
Research Assistant Professor, Department of Radiology
University of Wisconsin

William Sanders
Global Vice President, Chemical Development Operations
Veranova

Yuhua Hu
Head, US-EU CMC Management
WuXi XDC

Marie Zhu
Chief Technology Officer
WuXi XDC

Geoff Winters
Director & Functional Lead, ADC Process Development
Zymeworks

"World ADC San Diego is the premier conference for ADC developers. I learned how to make ADCs through World ADC, and I encourage everyone who wants to make a world class ADC to attend"

Angiex

"I have enjoyed attending the World ADC conference year after year because it is the ultimate event to get all of your ADC information in one place. Clinical updates, novel technologies, development insights, it's all here"

AstraZeneca

Pre-Conference Seminar Day | Monday, November 4, 2024

Introduction to ADCs Day 9.30 - 3.00

8.30 Check In, Morning Coffee & Light Refreshments

Are you new to the ADC field? If so, join our ADC 101 day to get your ADC knowledge up to scratch ahead of the scientific program days.

As more companies enter the ever-growing antibody-drug conjugate field, this seminar day will provide you with the critical knowledge gained over years of research and failed clinical trials that culminated in the presently approved ADCs and booming innovation in the field.

Led by long-standing experts & KOLs in the field, join this one-stop-shop of ADC learning **to establish a core understanding of the essential elements in ADC discovery and early development**.

John Lambert
Independent Consultant & Honorary Professor
Queens University Belfast

David Bramhill
President & Founder
Bramhill Biological Consulting

9.30 The morning session will cover:

- Gaining familiarity with the fundamental early learnings that inform ADC design
- Learning about the key insights that allowed early investigators to overcome the initial challenges that hindered early ADC programs
- Evaluating payload choices for ADCs
- Reviewing linker design chemistry and what it can bring
- Understanding the impact of conjugation site selection on ADCs

12.30 Lunch & Networking

1.30 The afternoon session will cover:

- Gaining an understanding of the biological aspects of ADCs
- Selecting the most appropriate ADC target
- Choosing an optimum antibody format
- Analyzing the choices and trade-offs in utilizing the chemistry ADC toolbox
- Assessing key factors in the evaluation of efficacy information from *in vivo* preclinical models

3.00 End of Introduction to ADCs Day

"A different type of conference than any that I have experienced before. It was not just simple presentations, but also a place for discussion and study together"

Chong Kun Dang Pharm

Pre-Conference Seminar Day | Monday, November 4, 2024

15th ANNUAL WORLD adc SAN DIEGO 2024

8.30 Check In, Morning Coffee & Refreshments

2nd Novel Targeting Moiety & Payloads Day

Chair: James Palacino, Head of Research, **Orum Therapeutics**

ADC design innovation continues to thrive, with more "XDC" conjugates showcasing non-traditional payloads and next generation targeting moieties expanding the applications of ADCs in oncology and beyond. Attend this seminar to **stay on top of cutting-edge DAC, dual payload and high DAR ADC, and small molecule drug conjugate development and more**

Showcasing Degrader Antibody Conjugates & Catalytic Payloads

9.30 Exploring a Novel Antibody-Degrader Conjugate Against Small Cell Lung Cancer

- Outlining antibody-degrader conjugate discovery and development
- Leveraging the catalytic mechanism of action of degrader payload
- Assessing promising candidate high potency and tolerability

James Palacino, Head, Research, **Orum Therapeutics**

5th Toxicity Day

Chair: Rakesh Dixit, President & Chief Executive Officer, **Bionavigen Oncology**

Despite the ongoing successes of ADCs reshaping oncology treatments, toxicity remains a major hurdle to ensure drug safety in clinical development. Join these sessions to **learn and debate ADC off-target toxicity, model selection and mitigation strategies, and for the first time, hear clinicians' perspective on dealing with ADC toxicity and widening the therapeutic index**

Identifying the Contributing Factors for ADC On & Off-Target Toxicity

9.30 Evaluating Methods to Characterize & Mitigate ADC Toxicity

- Discussing on and off-target toxicities of ADCs
- Highlighting strategies to mitigate ADC toxicity
- Optimizing preclinical discovery and development strategies to mitigate toxicity
- Tackling ADC clinical toxicity concerns in the clinic and innovative mitigation strategies

Rakesh Dixit, President & Chief Executive Officer, **Bionavigen Oncology**

2nd Biomarker & Patient Selection Day

Chair: Lara McGrath, Senior Director, Translational Medicine, **AstraZeneca**

Best demonstrated by Elahere's journey to full approval, fine-tuned biomarker development and patient selection is fundamental to ensure optimal ADC clinical performance. Don't miss **expert sessions spanning ADC biomarker discovery, translational investigation to inform patient population benefit, and clinical trial patient selection strategies**

Delving into ADC Biomarker Discovery & Biomarker-based Development

9.30 Delving into ADC Biomarker Investigation to Retrospectively Enrich Patient Trial Populations & Evaluate ADC-Immunotherapy Combinations

- Exploring genomic biomarkers to inform ADC patient selection and precision oncology clinical development
- Leveraging real world data to investigate genomic signatures and retrospectively identify enriched patient populations
- Understanding biomarkers to identify synergy in ADC-immunotherapy combinations

Alireza Tafazzol, Senior Scientist II, Oncology Bioinformatics, **AbbVie**

8th ADCs in Combination Day

Chair: Jay Harper, Director, Tumor Targeted Delivery, Early Oncology, **AstraZeneca**

ADC combinations have been the talk of the town as ADCs look to become standard of care oncology treatments. As the number of ADC combination therapies rapidly grow, join this seminar day to **best understand ADC combination rationale, study design, and case study applications across checkpoint inhibitors, immunotherapeutic agents, and ADCs in sequence**

Reviewing ADC Combination Strategies Pushing Forward Oncology Treatments

9.30 Reflecting on ADC Combination Development in 2023 & Highlighting Future Opportunities

- Optimizing strategy for ADC combinations
- Overviewing exciting ADC combination data generated in 2023 and 2024
- Looking to the future: what are the next steps for progressing ADC combinations?

Jay Harper, Director, Tumor Targeted Delivery, Early Oncology, **AstraZeneca**

NEW 1st Pharmacology Day

Chair: Eshita Khera, Principal Scientist II, **Novartis**

Underpinned by the recent FDA guidance release on designing clinical pharmacology studies for ADCs, don't miss this brand-new seminar day led by PK/PD and clinical pharmacology experts **to explore pharmacodynamic markers and modeling, dose optimization in early clinical development, and best strategies for ADC pharmacology strategy**

Evaluating ADC PK/PD Modeling & Exploring Early Dose Optimization

9.30 Non-clinical PD Modeling Delving Into ADC Payload MoA Characterization

- Exploring how the ADC landscape is dominated by pan-cytotoxic payloads
- Discovering the next era of ADCs breaking the mold of pan-cytotoxicity for selective mechanisms of action like protein degraders
- Designing such complex ADCs efficiently guided by quantitative PK/PD modeling

Eshita Khera, Principal Scientist II, **Novartis**

3rd Bioanalytical & Process Analytical Day

Chair: Hetal Sarvaiya, Director, QTAS (DMPK-BA), **AbbVie**

Accurately and efficiently characterizing PK, stability, and ADME *in vivo* is crucial to best inform ADC bioanalytical strategy and clinical trial design. Previously called the CQA & Bioanalytics Day, join your bioanalysis peers to **uncover the latest bioanalytical and analytical technological developments and applications to best set up your ADC bioanalytical characterization for success**

Showcasing Best-in-Class Bioanalysis to Inform ADC Bioanalytical Strategy

9.30 Exploring Development & Applications of a Novel Method for LC-MS ADC Preclinical Bioanalysis

- Outlining a novel method of LC-MS preclinical bioanalysis to decrease reagent usage and generate multiple readouts for ADCs
- Evaluating method development and optimization
- Highlighting readouts from real-world study and testing data

Vikram Shenoy, Senior Scientist I, QTAS (DMPK-BA), **AbbVie**

6th CMC Day

Chair: Weijun Li, Senior Director, Biologics Analytical Development & CMC Team Lead, **Exelixis**

As more ADCs advance towards late-stage development and regulatory submissions, maintaining and elevating CMC capability and strategy remains hugely important. Join this focused seminar day to **explore and discuss process scale up, efficient tech transfer, and regulatory CMC best practices across late-stage and commercial ADC development**

Supercharging Efficient Scale Up & Tech Transfer of ADC Process

9.30 High Purity Payload Linker: Preparative Chromatography… But Not Only

- Exploring preparative chromatography, a great tool for phase 1 and late phase programs
- Outlining development and integration of the chromatography step in payload linker manufacturing processes
- Combining payload and ADC conjugation on the same site, a good way to speed-up the development phase

Bertrand Cottineau, R&D Group Head, **Axplora**

Melanie Derde, Head, Bioconjugation Operations, **Axplora**

Pre-Conference Seminar Day | Monday, November 4, 2024

15th ANNUAL WORLD adc SAN DIEGO 2024

2nd Novel Targeting Moiety & Payloads Day

10.00 Showcasing Ongoing Development of a Degrader-Antibody Conjugate

- Outlining considerations for next generation of ADC
- Designing novel linker-payloads with non-cytotoxic mechanisms
- Exploring degrader antibody conjugate implications for unmet medical needs

Dongzhou Jeffrey Liu, Chief Scientific Officer & President of Global R&D, **Huadong Medicine**

10.30 Expanding ADC Therapeutic Potential: Multi-Payload Conjugates & the CysTyr Platform

- Design and assembly Multi-Payload Conjugates leveraging validated building blocks and an innovative conjugation technology using native amino acids
- Screening payload combinations for enhanced anti-tumor activity and exploring tunable DAR to match potency for multi-payload combinations
- Preclinical evaluation of Multi-Payload Conjugates and pathway to the clinic

Marco Lobba, Co-founder & Chief Executive Officer, **Catena Bio**

5th Toxicity Day

10.00 Toxicology Characterization & Selection of Top1i Drug-Linker & Conjugate

- Optimizing an ADC through modifications to the linker-payload
- Toxicity screening of linker-payload combinations to inform final ADC design
- Toxicology characterization of a novel Top1i ADC

Laura Kreckler, Senior Principal Research Scientist, **AbbVie**

10.30 Understanding the Drivers of Target Independent Toxicities Associated with ADCs & Solutions to Overcome Them

- Reviewing and understanding the drivers of efficacy limiting, target independent toxicities associated with ADCs
- Characterizing ADC properties and performance that can address these target independent toxicities
- Discussing approaches that move off the ADC platform to solve target-independent ADC toxicities

Travis Biechele, Vice President, Research, **Shasqi**

2nd Biomarker & Patient Selection Day

10.00 Developing Novel Biomarkers for ADC Therapeutics From Genomic Signatures to Enzyme Activity

- Identifying ADC biomarkers from genomic signatures
- Exploring biomarkers for ADC payloads and linkers
- Investigating biomarkers from ADC-immune combinations

Jian Chen, Director, Translational Research & Preclinical Development, **BioAtla**

10.30 Leveraging 17p Deletion as a Biomarker & Patient Selection Tool for Amanitin Payload ADCs

- Breaking down biology and mechanism of action of 17p deletion and improved sensitivity to amanitin payload ADCs
- Assessing 17p deletion as a biomarker for amanitin payloads
- Exploring strategy for leveraging 17p deletion biomarker as a patient selection measure, contextualized with HDP-101

Anikó Pálfi, Director, Biochemistry & Cell Biology, **Heidelberg Pharma**

8th ADCs in Combination Day

10.00 Uncovering the Rise of ADC Combination Clinical Trials

- Reviewing how the ADC combination trial landscape have grown over the years
- What combination strategies have been explored so far?
- Discussing the trends observed in the space and an outlook on what's to come ahead

Shailee Patel, Scientific Liaison Analyst, **Beacon**

10.30 Ifebemtinib in Combination With ADCs - Enhancing Efficacy & Improving Safety Profile

- Demonstrating preclinical evidence of FAKi ifebemtinib reducing the fibrotic barrier and enhancing ADC penetration across payloads to boost efficacy
- Explaining interstitial pneumonitis dose limiting toxicity and outlining Ifebemtinib effectiveness in preventing/treating Enhertu induced interstitial pneumonitis
- Showcasing how Ifebemtinib can potentially improve the therapeutic window via increasing local exposure and reducing the DLT

Zaiqi Wang, Chief Executive Officer, **InxMed**

1st Pharmacology Day NEW

10.00 Evaluating Learnings of Preclinical to Clinical Dosing Between Approved & Non-Approved ADCs

- Contrasting translational dosing between approved vs non-approved ADCs
- Combining experimental and computational modeling to evaluate clinically effective ADC dosing in mice
- Outlining minimal effective dose considerations to improve translation into the clinic

Greg Thurber, Associate Professor & Chair, Graduate Education, **University of Michigan**

10.30 Exploring Dose Selection in Early Clinical Development for ADCs

- Discussing the uniqueness in the dose selection strategy for ADCs
- Reviewing Pfizer clinical pharmacology learnings from ADCs in early clinical development
- Utilizing modeling andn simulation in ADC dose selection/optimization

Flavia Storelli, Clinical Pharmacologist, Oncology Division, **Pfizer**

3rd Bioanalytical & Process Analytical Day

10.00 Bioanalysis & Learnings of *In Vivo* Biotransformation on ADC PK Measurements

- Outlining case study examples of ADC *in vivo* biotransformation affecting PK assays
- Explaining how changes in DAR and CDR biotransformation *in vivo* can impact PK measurement
- Applying learnings to mitigate impact on PK properties for ADC program and wider ADC development

Ling He, Senior Director, Clinical Bioanalysis, **Daiichi Sankyo**

10.30 Understanding ADC Charge Variants & DAR Characterization

- Reviewing how charge variants are an important facet to understand in an ADC that regulatory agencies expect this to be controlled
- Exploring the contribution from linker/payload as well as the antibody can contribute variants
- Outlining how innovative strategies were developed to address the contribution of each variant sources

Simon Letarte, Director, Extended Structural Characterization, **Gilead Sciences**

6th CMC Day

10.00 Accelerating Development & Scale Up of Robust ADC Processes

- Understanding of reaction and purification processes via mathematical modeling, to drive process understanding and enable efficient scale up
- Driving real time data-rich process development using integrated process analytical technologies
- Reactor scale-up assessment including modeling reactor hydrodynamics and heat transfer capabilities in alignment with process requirements

Laurie Mlinar, Associate Director/Principal Research Scientist II, **AbbVie**

10.30 CMC Considerations for Manufacturing & Control of Antibody-Drug Conjugates

- Highlighting unique characteristics of ADCs and providing insights and guidance for navigating ADC CMC development
- Focusing on material management, facility design requirements, and process control to achieve high-quality ADC production
- Addressing impurity control strategies and other factors to maintain product integrity, and ensure the delivery of safe and effective biopharmaceutical products

Wei Gong, CMC Operation General Manager, **Aton Biotech**

Virtual Presentation

11.00 Morning Break & Networking

CONTENTS

Pre-Conference Seminar Day | Monday, November 4, 2024

15th ANNUAL WORLD adc SAN DIEGO 2024

2nd Novel Targeting Moiety & Payloads Day

Showcasing Novel XDCs & Conjugation Chemistry to Inform Innovative ADC Design

11.30 Showcasing Development of a Novel Small Molecule Dual Payload Drug Conjugate Targeting PSMA

- Detailing novel conjugate design and development against traditional ADCs
- Explaining dual radiopharmaceutical and immune stimulating payload design and mechanism of action
- Outlining ongoing preclinical development and studies to prepare for future clinical trials

Labros Meimetis, Research Assistant Professor, Department of Radiology, **University of Wisconsin School of Medicine & Public Health**

12.00 Innovations for the Next Generation of Glycosite-Specific ADCs

- Exploring innovative designs to improve the therapeutic window of glycosite-specific ADCs
- Applying glycosite-specific conjugation to develop next generation antibody conjugates

Chung-Yi Wu, Chief Executive Officer, **CHO Pharma**

5th Toxicity Day

Utilizing Preclinical Models to Best Predict ADC Clinical Toxicity

11.30 Leveraging Preclinical Models to Investigate & Characterize Antigen-Independent ADC Ocular Toxicities

- Assessing antigen-independent ocular toxicity across different ADC programs
- Characterizing mechanism of action of ADC linker-payloads inducing corneal injuries seen in patients
- Utilizing different models to investigate antigen-independent ocular toxicities

Forgivemore Magunda, Principal Pathologist, **Pfizer**

12.00 Improving Predictability-Deciding on the Best *In Vivo* Model in Order to Replicate Toxicities Clinically

- Optimizing an ADC platform to minimize platform off-target toxicity
- Comparing two NaPi2b ADCs produced using two different platforms, improving safety and efficacy both pre-clinically and clinically
- Leveraging the rat, versus NHPs, for investigative mechanistic studies

Scott Collins, Director, Non-Clinical Development, **Mersana Therapeutics**

2nd Biomarker & Patient Selection Day

Bridging ADC Biomarker Development into the Clinic

11.30 Biomarker-based Development of GQ1011: First In Class ADC Targeting FGFR3 In Solid Tumors

- GeneQuantum's pioneering ADC technologies behind GQ1011's development
- Prevalent FGFR3 mutations in mUC and other solid tumors
- Biomarker-driven non-clinical studies for GQ1011's clinical development
- Precise clinical translation strategy based on biomarkers

Yajun Sun, Executive Director, Non-Clinical, **GeneQuantum Healthcare**

12.00 Exploring Different Approaches to Precision ADC Development & Patient Identification

- Advancing machine learning and digital pathology tools to quantify target expression from IHC
- Leveraging molecular testing, like NGS panels, to identify individuals more sensitive to ADC therapies
- Best practices for incorporating ctDNA into your translational science strategy for ADCs

Lara McGrath, Senior Director, Translational Medicine, **AstraZeneca**

8th ADCs in Combination Day

Exploring ADC Combinations in Immuno-Oncology & Beyond

11.30 Outlining a Rationale-Based Approach for Combining ADCs With Immune Checkpoint Inhibitors

- Exploring ongoing development and promise of ADC – immune checkpoint inhibitors
- Detailing rationale for combination therapy approach
- Summarizing the potential of ADC – checkpoint inhibitor combinations to boost immune response

Harald Haeske, Chief Medical Officer, **Oxford BioTherapeutics**

12.00 ADC-Antibody Therapeutic Combinations to Improve ADC Efficacy & Immune Response

- Discussing rational design of ADC/antibody combinations show improvement in preclinical animal model efficacy
- Combining ADCs with engineered antibodies can enhance ADC distribution and trafficking
- Outlining protein engineering strategies can enhance ADC efficacy with increased stimulation of the immune system

Greg Thurber, Associate Professor & Chair, Graduate Education, **University of Michigan**

1st Pharmacology Day NEW

Exploring ADC Pharmacology Strategy Under Project Optimus & Recent FDA Guidance

11.30 Roundtable Discussion: Fine Tuning ADC Dose Optimization Strategy - Evaluating Clinical Trial Design, Bioanalysis, Quantitative Methodologies & Regulatory Attitudes

Join individual table discussions moderated by clinical pharmacology leaders with prepared discussion points surrounding ADC pharmacology study design. Make sure you come with your thoughts and questions prepared!

- ADC bioanalysis: how and what do we want to characterize?
- Exploring quantitative methodologies across translational PK/PD, exposure response, clinical utility index to optimize dose response
- Discussing ADC dose optimization strategies - what are the key considerations given the FDA guidance on ADC pharmacology studies?
- Evaluating challenges and opportunities in clinical trial design

Amit Garg, Executive Director, Clinical Pharmacology Oncology, **Pfizer**

Heller Chen, Senior Clinical Pharmacologist II, **Gilead Sciences**

Eshita Khera, Principal Scientist II, **Novartis**

End of 1st Pharmacology Day

3rd Bioanalytical & Process Analytical Day

Capturing & Characterizing the Ideal ADC Analytical Package

11.30 Development of an Analytical Control Strategy to Assess ADC Biological Activity

- Reviewing the importance of developing a functional cell-based assay in early product development
- Reflecting mechanism(s) of action and implementation of CQA-based biological characterization assessment to inform process development and monitor impact of process and manufacturing changes
- Characterizing impact of specific PTMs, mode of conjugation and DAR on biological potency, Fc binding and effector functions
- Exploring the selection of target and effector cell models for assessment

Petra Bennington, Director, Analytical Research & Development, **Merck & Co**

12.00 Roundtable Discussion: Harnessing Technologies & Workflows for ADC Bioanalysis & Analytical Characterization

- Evaluating the individual needs for ADC PK, ADME and stability analysis *in vivo* compared to traditional biologics and other modalities
- Weighing up bioanalytical and analytical technologies: what is at the cutting edge in 2024?
- Debating the best bioanalytical and analytical workflows to streamline ADC characterization

Hetal Sarvaiya, Director, QTAS (DMPK-BA), **AbbVie**

End of 3rd Bioanalytical & Process Analytical Day

6th CMC Day

Developing & Maintaining ADC CMC Capability at High Scale Production

11.30 Navigating the Challenges in Lyophilization Process Development & Scaleup of ADC Drug Products

- Elucidating process optimization and modeling approaches to develop a robust lyophilization process in accelerated timeline
- Discussing the ADC product attributes that influence lyophilization process development
- Evaluating considerations for technology transfer to commercial manufacturing sites, assessing failure modes and developing a strong control strategy

Harshil Renawala, Senior Scientist, Sterile Drug Product Commercialization, **Merck & Co**

12.00 Your Journey to a Seamless ADC Drug Product Tech Transfer With Lonza

- Exploring best practices and case studies in ADC tech transfer for your drug product
- Learning about Lonza new drug product high potent capabilities from preclinical development to commercial supply
- Finding out the right entry points to collaborate with Lonza Drug Product Services, offering tailored paths and solutions for every phase of your ADC development process

Pierre Landais, Director, Commercial Development, Drug Product Services, **Lonza**

Wei Han Tan, Manager, Technical Sales & Customer Proposals, Drug Product Services, **Lonza**

12.30 Lunch & Networking

Pre-Conference Seminar Day | Monday, November 4, 2024

15th ANNUAL WORLD adc SAN DIEGO 2024

2nd Novel Targeting Moiety & Payloads Day

Showcasing Dual Payload & High DAR ADC Design

1:30 Versatile Drug Bundle Technology: Efficiently Developing High-Efficacy, Stable ADCs With High DAR (8 or 12) & Optimized Dual Payloads

- Creating and optimizing versatile drug bundles with different drug combinations and ratios
- Sharing CHO-TEM Technology allowing linkage of 4 drug bundles,each containing 2 or 3 drugs from two categories
- Discussing development of high-efficacy and stable ADCs with high DAR (8 or 12) and dual drugs

Hsing-Mao Chu, Chief Executive Officer, **T-E Meds**

2:00 Exploring Development of Dual Payload Conjugates & Innovation in High-DAR ADCs

- Utilizing a cell-free platform to create novel ADCs
- Implementing site-specific technology to improve efficacy by increasing DAR
- Creating dual payload ADCs with enhanced tumor killing through synergistic payloads

Daniel Calarese, Director, Innovation & Strategy, **Sutro Biopharma**

2:30 Showcasing A Proprietary Site-selective Dual-Payload Antibody Conjugation Platform

- Introducing a proprietary dual-payload conjugation design to overcome drug resistance and tumor heterogeneity
- Displaying preclinical evidence of proprietary dual-payload conjugates against cancers

Sonny Hsiao, Founder & Chief Executive Officer, **Acepodia**

5th Toxicity Day

Characterizing ADC Toxicity & Exploring Mitigation Strategies

1:30 "SORTI"ng Out the Multiple Benefits & Safety Profile of SORT1+ TechnologyTM

- Discussing the rationale for targeting SORT1 receptor in solid tumor expression and rapid internalization function
- Overviewing TH1902 POC FIH Data to understand how the toxicity profile differs from that of its payload
- Exploring the ongoing clinical development of TH1902, focusing on dose optimization to improve efficacy and safety

Christian Marsolais, Senior Vice President & Chief Medical Officer, **Theratechnologies**

2:00 Envisioning the Clinician's Perspective on ADC Clinical Development & Managing Safety Issues

- Outlining lessons learned from previous ADC clinical trials in terms of adverse effects
- Explaining ADCs as 4th generation chemotherapies and outlining strategies to mitigate toxicity issues
- Suggesting future ways to reduce toxicity with enhanced efficacy to incrementally increase therapeutics index in the clinic

Do-Hyun Nam, Professor, Department of Neurosurgery, Samsung Medical Center, **Sungkyunkwan University School of Medicine**

2nd Biomarker & Patient Selection Day

Optimizing Strategies & Understanding Benefits for ADC Patient Selection

1:30 Unlocking Superior ADC Response by Assessing Tumor Fibrosis (PRO-C3)

- Tumor fibrosis reduce the effectiveness of ADC's by creating a physical barrier that make it hard for the drugs to reach and work in the tumor
- PRO-C3 is a biomarker of tumor fibrosis that can be measured in serum/plasma and have a letter-of-support from the US FDA for prognostic enrichments strategies across solid tumors
- PRO-C3 can identify patients that are more or less likely to benefit from ADC's and enable better response rates, survival outcomes, and successful drug development

Nicholas Willumsen, Director & Head, Oncology, **Nordic Bioscience**

2:00 Investigating Biomarkers to Inform Clinical Decisions & Maximize ADC Benefit

- Utilizing biomarkers to support characterization of ADC payload unique mechanism of action
- Leveraging biomarker analysis to select patient populations to benefit from specific ADCs
- Informing clinical development with takeaways from payload biomarker investigation

Yan Zhang, Senior Director, Translational Sciences, **Eisai**

8th ADCs in Combination Day

Evaluating Strategies & Benefits of Delivering ADC in Sequence

1:30 Investigating Combinations & Sequences to Work Around ADC Drug Resistance

- Understanding ADC drug resistance mechanisms
- Leveraging preclinical data to assess ADC combination potential to overcome resistance mechanisms
- Looking forward to clinical assessment of ADC combinations combating drug resistance

Jay Mettetal, Senior Director, Oncology Bioscience, **AstraZeneca**

2:00 Roundtable Discussion: What Are the Benefits & Limitations of ADC Combinations?

- Join this closing roundtable session with leaders in the ADC combinations field to discuss, debate and evaluate the opportunities and challenges in combination partner selection, sequencing of partners, dual payloads, and more

Jay Harper, Director, Tumor Targeted Delivery, Early Oncology, **AstraZeneca**

6th CMC Day

Preparing for ADC BLA Submissions & Setting the Right Specifications

1:30 Contextualizing Challenges & Best Practices for ADC Regulatory Submissions

- Evaluating what to prepare and how to organize materials for ADC BLA submissions
- Leveraging health authority interactions during development to refine the CMC strategy
- Using risk assessments to address accelerated development timelines and to demonstrate comparability due to process changes

Charles Morgan, Head, Regulatory CMC, **Denali Therapeutics**

2:00 Undergoing Late-Phase ADC Analytical & Stability Characterization Under Accelerated Timelines

- Breaking down the pieces from late-stage ADC analytical and stability data packages
- Assessing scale up strategy from limited scalability time points
- Navigating pressures from accelerated ADC development timelines

Yuting Huang, Senior Principal Scientist & Group Leader, **Pfizer**

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW

2:30 **Afternoon Break & Networking**

3:15 **Panel Session: Diversity & Inclusion in Oncology & ADC Clinical Trials**

NEW

Free to Attend With All Registration Passes

Ensuring diversity, inclusion, and a patient centric approach in clinical trials is crucial to encompass the broad range of lived experiences and diverse populations so that all patients can benefit from the fast-paced advances and innovations in ADC therapies. Attend this brand-new session led by oncology and patient advocates to **explore the significance and importance of D&I in ADC development, learn from mistakes in the past, understand the patient perspective, and hear successful case studies of implementing patient considerations in clinical trial design and recruitment** to ensure your ADC product development is representative to all patient populations.

Register your interest when you sign up to attend the conference, then look out for an email to secure your spot!

Highlights include:

- Exploring the current status and opportunities for improvement in D&I throughout ADC product development – what mistakes have been made in the past?
- Hearing case studies and company strategies to address and improve D&I in ADC clinical trials
- Explaining the clinical trial design and recruitment considerations from the beginning to make ADC products representative to all patient populations
- Breaking down takeaways of lived experience and incorporating learnings to help design ADC clinical trials

Moderator

Radhika Balasubramani
Director, Technical Product Steward, Antibody Drug Conjugates
Merck & Co

Ricki Fairley
Chief Executive Officer & Co-Founder
Touch, The Black Breast Cancer Alliance

Adalynn Harris
President & Chief Executive Officer
Equity Bridge

Mary Elmer
Executive Director, Patient Engagement Oncology
Merck & Co

4:15 **End of Pre-Conference Seminar Day**

4:30 **Evening Ambassador's Reception**

At the end of the pre-conference seminar, this invitation-only, informal evening reception is your perfect opportunity to reunite with old friends and meet new colleagues in the ADC field as the community returns to San Diego. Ahead of the main conference day, grab a drink of your choosing and network with the other attendees to strengthen and establish scientific and business relationships with your fellow innovators in the ADC field.

Hosted By: ABZENA Moving medicine forward.

6:30 **End of Ambassador's Reception**



Scientific Program Day One | Tuesday, November 5, 2024

7.00 **Check In, Morning Coffee & Refreshments**

7.55 **Chair's Opening Remarks**

Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics

Moving the Needle Forward in 2024 & Beyond: What are the Next ADCs to Re-Shape the Field?

8:00 **Panel Discussion: Contextualizing the Ongoing Growth & Success of the ADC Field & Envisioning the Best Route Forward for ADC Innovation**

- Reflecting on the past and envisioning the future of the ADC field: spanning upcoming approvals, exciting targets, novel linker-payloads, conjugation technologies, and combination therapies
- Deep-diving into recent clinical trials – what ADCs have broken the perceived clinical expectations for success?
- Debating rationale of going after new targets and using novel payloads against iteratively improving the validated successes in the field – what are predictions for the next ADC breakthrough?
- Diversifying your ADC portfolio across indications, targets, and ADC components to be on top of the next wave of ADC innovation

Moderator

Jeffrey Settleman
Chief Scientific Officer, Oncology R&D
Pfizer

Shawn Zhang
Chief Scientific Officer
Ambrx, a Johnson & Johnson Company

Puja Sapra
Senior Vice President, Biologics Engineering & Oncology Targeted Discovery, Oncology R&D
AstraZeneca

Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics

Mary Jane Hinrichs
Senior Vice President, Global Head of Early Development
Ipsen

Scott Peterson
Head, ADC Discovery & Cancer Immunology
Pfizer

9:00 **From IND to Long Term Commercial Supply: a Step Ahead Against the Challenges of the Bioconjugates**

- Serving the innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
- Overview on conjugation and fill/finish capabilities
- Delivering important updates on conjugation and fill-finish capacity

Maria Elena Guadagno
Technical Operations & Business Executive Director
BSP Pharmaceuticals

9:30 **TROP2 ADC Development: Exploring the Datopotamab Deruxtecan Mechanism, Clinical Efficacy, & Future Directions**

- Delving into the intricacies of Dato-DXd mechanism of action and the innovative approach in developing ADCs with the DXd linker-payload technology
- Examining the comprehensive late-stage clinical data for Dato-DXd, highlighting its clinical efficacy and safety profile
- Discussing the critical insights gained from the development of Dato-DXd, and outline the strategic next steps for its clinical application and further development

Ricardo Zwirtes
Executive Director, Global Clinical Lead
Daiichi Sankyo

10.00 **Morning Break & Networking**

As the ADC community is reunited all under one roof at the world's leading and biggest industry forum, use this valuable time to reconnect with your peers, meet fresh faces, and visit exhibitor booths to make new and lasting scientific and business "linkers" with the wide range of attendees. This is a dedicated time to have face-to-face interaction with many of the brightest minds working in the ADC field and establish meaningful relationships - don't forget to enjoy some refreshments before we split off into the six conference tracks.

Scientific Program Day One | Tuesday, November 5, 2024

Discovery Chemistry	Cellular Biology	Translational	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain
Chair: Thomas Nittoli, Senior Director, **Regeneron**	**Chair: Kevin Hamblett,** Senior Director, ADC Biology, **Pfizer**	**Chair: Rakesh Dixit**, President & Chief Executive Officer, **Bionavigen Oncology**	**Chair: Patrick Zweidler-McKay**, Former Executive Medical Director, **ImmunoGen**	**Chair: Lisa McDermott,** Director, Process & Analytical Development, **MilliporeSigma**	**Chair: Geoff Winters,** Director & Functional Lead, ADC Process Development, **Zymeworks**
Optimizing the Classics & Exploring Next Generation ADC Payloads to Guide ADC Chemistry & Design	**ADC Target Showcase & Investigation for Novel Therapeutic Development**	**Evaluating Best-in-Class Translational Studies to Inform ADC Preclinical Development**	**Showcasing Cutting-Edge Clinical Development of Late-stage ADC Candidates**	**Analytical Technologies & Applications: Tackling Characterization of Complex ADC Molecules**	**Exploring Strategies & Risk Assessments for ADC Manufacturing & Development**
11.00 **Evaluating Design & Optimization of Novel Exatecan-based Payloads** • Assessing the evolution of novel exatecan payloads • Exploring preclinical evaluation of novel exatecan payloads • Navigating the challenges of exatecan-based ADCs **Paul Hogg**, Vice President, Medicinal & Protein Chemistry, **ADC Therapeutics**	11.00 **Targeting Mesenchymal Tumors With a Novel Antibody Drug Conjugate** • Reviewing how despite progress made in systemic and local treatments of mesenchymal tumors, there is a particular high unmet need in patients with locally aggressive and reoccurring disease • Discussing target choice and the tailored design of linker-payload and conjugation modality for this disease setting • Utilizing a clinically validated site-specific beta-glucuronide linker to enable tumor selective payload release while mitigating toxicity **Martin Steegmaier**, Chief Scientific Officer, **SOTIO Biotech**	11.00 **Raludotatug Deruxtecan (R-DXd), a Cadherin-6-directed ADC With a DNA Topoisomerase I Inhibitor DXd** • Gaining an overview of the DXd-ADC technology platform • Detailing preclinical data of R-DXd • Exploring clinical data and development plan of R-DXd **Shotaro Nagase**, Researcher, Discovery Research Laboratories I, **Daiichi Sankyo**	11.00 **Showcasing Clinical Update & Learnings for Luvelta Targeting Folate Receptor Alpha** • Gain an update on Phase 2/3 trial in patients with recurrent, platinum resistant ovarian cancer (OC), endometrial cancer (EC) and AML • Discuss the impact of ADC design on anti-tumor activity and platform adverse events • Review clinical combination strategies with Luvelta in ovarian cancer and beyond **Hanspeter Gerber,** Chief Scientific Officer, **Sutro Biopharma**	11.00 **Assessing Analytical Methods for ADC DAR Characterization & Control Strategy** • Investigating high-resolution mass spectrometry and reduced HIC methods to assess ADC DAR • Highlighting real-life advantages and discrepancies of different analytical methods • Contextualizing findings to inform DAR characterization workflow development and quality control **Yuan Ren**, Principal Scientist Scientist, Chemical Process Development, Analytical Chemistry, **Bristol Myers Squibb**	11.00 **Exploring Technical Challenges & Opportunities in Early-Stage ADC Development & Manufacturing** • Evaluating challenges and opportunities specific to early-stage ADC development manufacturing • Highlighting strategies across drug-linker, mAb, DS, and DP manufacturing • Ensuring effective clinical supply for early-stage ADCs **Engin Ayturk**, Senior Director, CMC Bioconjugation, Process Development & Manufacturing, **Exelixis**
Discovery Chemistry	Cellular Biology	Translational	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain

CONTENTS

Scientific Program Day One | Tuesday, November 5, 2024

Discovery Chemistry

11.30 Improved Efficacy & Reduced Toxicity of ADCs With OHPAS Linker, PMT, & Nexatecan

- Overview of the OHPAS linker: a highly stable, hydrophilic, disulfide-based cleavable linker for phenol-containing payloads
- Discussing PMT's potential to reduce non-selective uptake in normal cells, thereby improving the selectivity and efficacy of ADCs
- Enhancing ADC efficacy and the maximum tolerated dose (MTD) using Nexatecan, an OHPAS-compatible camptothecin derivative

Yosup Rew, Chief Technology Officer, **IntoCell**

12.00 Introduction to Radioconjugates & the Promise of Theranostics for the Delivery of Molecularly Targeted Radiation

- Overviewing the current status of radioconjugate development
- Showcasing data from a collaborative radioconjugate study
- Outlining approaches to radioconjugate development in the clinic

Frank Comer, Director, Tumor Targeted Delivery, Early Oncology Discovery, **AstraZeneca**

Cellular Biology

11.30 Opening the Barn Door to ADC Discovery

- Generating naturally optimized, fully human custom immune repertoires in multiple host species to fit any target product profile
- Mining our repertoires using high throughput B cell discovery workflows augmented by AI-guided selections
- Explaining antibody discovery capabilities applications to ADCs across on-target specificity, high affinity, developability, and versatility to fit a plethora of molecular formats

Eric Vajda, Vice President, Preclinical R&D, **OmniAb**

12.00 Showcasing ADC Development Against Claudin Family Targets – Claudin 6 & Claudin 18

- Highlighting the potential of the Claudin family of proteins as ADCs target with an emphasis on CLDN6 and CLDN18.2
- Showcasing the preclinical efficacy of novel ADCs against CLDN6 and CLDN18.2
- Receiving an update on the ongoing phase I clinical studies with these ADCs

Martina McDermott, Adjunct Assistant Professor, **UCLA**

Translational

11.30 Expanding ADC Therapeutic Index Through Site-Specific Bioconjugation & Tumor Selective Payload Release & Activation

- LCB's site-specific ConjuAll™ platform enables discrete DAR ADCs with circulation stable bioconjugation
- LCB's proprietary beta-glucuronidase technology enables unprecedented preclinical therapeutic indexes through tumor selective release and activation of payload
- Early clinical safety and efficacy across payload classes validate the LCB platform

Stephen Slocum, Director, Drug Development, Project Lead, **LigaChem Biosciences**

12.00 Preclinical Development of a Novel PBD-Based ADC Against CD45 for Antigen Specific Depletion of Hematopoietic Stem Cells & Hematological Malignancies

- Introducing CD45, shielding approach and rational design of a PBD based ADC with a non-cleavable linker
- Evaluating preclinical data illustrating CD45 specific depletion of the entire haematopoietic system
- Assessing preclinical data illustrating that pairing this ADC with transplanted shielding engineered human HSCs enables selective eradication of leukemic cells with preserved haematopoiesis

Patrick Van Berkel, Chief Scientific Officer, **ADC Therapeutics**

Clinical Lessons

11.30 AI Spatial Biomarkers & Diagnostics for ADC Patient Selection

- Discussing how the MoA of ADCs and bispecifics warrant an AI-powered spatial biomarker approach for accurate patient selection
- Outlining how novel, AI-powered spatial biomarkers are being deployed for trial enrollment
- Exploring how the exponential rise in ADC and bispecific trials and approvals will result in a new generation of diagnostics to aid physicians in treatment selection and what it means for drug developers

Jason Reeves, Director, Application Science, **Nucleai**

12.00 Evaluating the Breadth & Depth of I-DXd (Anti-B7-H3 ADC) Efficacy in Solid Tumors

- Targeting B7-H3 with I-DXd demonstrates efficacy in an array of solid tumors
- I-DXd efficacy correlates with B7-H3 expression in a subset of tumor types with high prevalence of B7-H3 expression
- I-DXd is a promising agent for SCLC

Caleb Lee, Executive Director, **Daiichi Sankyo**

Process & Analytical Development

11.30 Bringing Novel ADC Formats into the Clinic: Insights from the Process Development of Oligonucleotide Conjugates

- Learning about Lonza's capability of supporting the development and manufacture of an increasingly diversified landscape of ADC formats and associated processes
- Exploring process-related challenges and opportunities of novel ADC formats showcased by antibody-oligonucleotide conjugates
- Finding out how to benefit from Lonza's accelerated and integrated offering and end-to-end lifecycle support for ADCs

Hanna Wagner, Supervisor, Process Development Bioconjugates, **Lonza**

12.00 Leveraging Machine Learning Models to Predict ADC Post Translational Modifications

- Applying and optimizing published ML models to predict post-translational modifications in ADCs
- Detailing case of tweaking models to characterize a photo-sensitive payload impacting ADC degradation
- Highlighting significance of optimized machine learning model for future discovery and candidate selection

Nicole Swope, Senior Scientist, Analytical Sciences, **AstraZeneca**

Manufacturing & Supply Chain

11.30 Assessing the Capabilities of CMOs/CDMOs for Safely Handling Payloads & ADCs for Worker & Product Protection Purposes

- Assessment of the CMO for safely making the payloads and ADCs
- Quantitative risk and exposure assessment-development of Occupational Exposure Limits (OELs), Acceptable Surface Limits (ASLs) and Permitted Daily Exposures (PDEs)
- Quantitative exposure assessment for worker exposure purposes including validated industrial hygiene air sampling and surface sampling methods
- Reviewing Extractables and Leachables for Bioprocess Train and Container Closure Systems for patient safety

Allan Ader, Managing Director, **SafeBridge Consultants**

12.00 Taking on Risk Factors in ADC Manufacturing – How Much is Acceptable?

- Outlining effective risk management in ADC manufacturing to ensure consistency in product quality throughout the product life cycle
- Identifying key risks factors, inevitable and calculated, in the multifaceted ADC process from end to end
- Discussing risk mitigation with sustainability and quality at the core

Esohe Idusogie, Head, Process Quality & CMC Analytical ADC Therapeutics, **ADC Therapeutics**

Scientific Program Day One | Tuesday, November 5, 2024

15th ANNUAL WORLD adc SAN DIEGO 2024

Discovery Chemistry	Cellular Biology	Translational	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain
12.30 Development of a Site Specific & Versatile Conjugation Approach Based on Bacterial Transglutaminase & the Diels-Alder Cycloaddition Reaction • Explaining the versatility of maleimides that specifically conjugate to antibodies via cycloaddition reaction • Exploring design and synthesis of diene-containing linkers for site-specific transglutaminase conjugation • Evaluating *in vitro* and *in vivo* activity of the ADCs generated and assessing ADC stability • Highlighting the importance of collaborations with CROs for discovering and developing novel linker and conjugation technologies **Francisco Velasquez**, Senior Director, Chemistry, **Abzena**	**12.30 Accelerating Bispecific Discovery With the Alloy Common Light Chain Fully Human Transgenic Mouse Platform** • Introducing Alloy bispecific discovery services and best-in-class platforms • Creating Common Light Chain strains, ATX-CLC, to build bispecifics with better developability profiles by solving heavy and light chain pairing • Leveraging ATX-CLC Alloy to support bispecific discovery through format engineering and functional assessment to move candidates forward rapidly **Mike Schmidt**, Chief Scientific Officer, **Alloy Therapeutics**	**12.30 Catalent SMARTag® ADCs: Innovating What's Next** • Breaking down Topo1 bioconjugates success and discussing what innovations will yield differentiated molecules that can multitask in terms of MOA • Catalent's SMARTag® platform offers the solution, combining two payload classes ligated through industry-recognized stable linkers all on a single ADC • Presenting updated data on belotecan+MMAE conjugate using SMARTag platform with tandem-cleavage linkers to improve efficacy and tolerability and combine any two payloads of choice **Stepan Chuprakov,** Director of Chemistry, **Catalent Pharma Solutions**	**12.30 Breaking Down Expanded Clinical Data of ABBV-400 ADC Targeting c-Met** • Contextualizing design and clinical performance of ABBV-400 targeting c-Met • Describing extended clinical data package of ABV-400 safety and efficacy performance • Discussing future directions for ABV-400 in CRC and MET amplified tumors **Hua Fang**, Scientific Director, Clinical Development Oncology, **AbbVie**	**12.30 Phase & Product Appropriate Bioconjugate Development** • Exploring the differing development approaches of ADCs across the preclinical/ clinical/ commercial development spectrum • Traditional ADCs addressed oncological indications with targeted cytotoxic payloads. The bioconjugate landscape now encompasses a wide variety of modalities with differing modes of action and molecular structures • Exploring relevant examples of how the requirements for process and analytical development can vary between different bioconjugate modalities **Conor Barry**, Associate Vice President, Global Biologics Technical Lead, **Piramal Pharma Solutions**	**12.30 Empowering Successful Bioconjugation Manufacturing with Process Technology Innovation** • Assessing the challenges in ADC and bioconjugates manufacturing • Demonstrating XDC's powerful process platform and technology innovation • Exploring case studies on site specific conjugation process and manufacturing **Yuhua Hu**, Head, US-EU CMC Management, **WuXi XDC**

1.00 Lunch & Learn Presented By MilliporeSigma

Leveraging Novel Conjugation Chemistries for Site-Specific Conjugation	Bispecific ADCs: Navigating Mechanistic & Translational Development	Getting on Top of ADC Safety & Efficacy Characterization to Maximize Translation	Putting the Why Behind Performance in the Clinic to Set Up Early ADC Development for Success	Characterizing & Controlling Impurities to Improve ADC Quality	Efficiently Juggling the Pieces to Achieve Smooth ADC Supply Chain
2.00 Highlighting Novel Conjugation Technologies Spearheading the Transition Away From Stochastic Conjugation • Detailing the advantage of site-specific ADC conjugation • Showcasing preclinical data for a novel ADC bioconjugation method • Outlining considerations for future clinical investigations **Sayumi Yamazoe**, Associate Director, ADC Discovery, **Bristol Myers Squibb**	**2.00 Showcasing Development & Potential of a Bispecific ADC vs Traditional ADCs** • Exploring non-clinical data from ongoing bispecific ADC development • Understanding ADC molecule mechanism of action • Highlighting the benefit of bispecific ADCs for specific target combinations **Jinwon Jung**, Senior Director, Protein Engineering, **ABL Bio**	**2.00 Characterizing ADC Safety & Activity in Preclinical Development of STRO-004** • Translational strategy to support clinical development • Exploring safety profile in preclinical monkey studies • Evaluating PDX models to support indication selection • Characterizing exploratory biomarkers to support potential patient selection strategies • Looking ahead to potential combination strategies with immune-checkpoint inhibitors **Alice Yam**, Vice President, Drug Discovery, **Sutro Biopharma**	**2.00 Highlighting & Contextualizing Clinical Development of Rinatabart Sesutecan ADC** • Exploring ongoing clinical development of Rina-S ADC • Utilizing improved payload to improve clinical performance against comparable ADCs • Explaining use of hydrophilic linker with hydrophobic ADC payload **Edward Kavalerchik,** Senior Medical Director, **Genmab**	**2.00 Undergoing Deep ADC Characterization to Identify Low-Abundance Conjugatable Impurities** • Reviewing process control for Dolaflexin, a heterogeneous natural-polymer-based ADC platform • Discussing well-designed characterization methods to provide additional evidence of quality consistency • Discussing the application of MS to detect trace level of structure-related impurities **Yuanyuan Li**, Director, **Mersana Therapeutics**	**2.00 Roundtable Discussion: Assessing Bottlenecks & Opportunities to Streamline ADC Manufacturing Across Multiple Outsourced Partners** • Breaking down the challenges of navigating ADC development and manufacturing across multiple outsourcing partners • Debating top performing strategies to ensure smooth and timely ADC development across multiple manufacturing partners • Setting expectations with manufacturing partners: what works well and what can be improved?

CONTENTS

Scientific Program Day One | Tuesday, November 5, 2024

Discovery Chemistry	Cellular Biology	Translational	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain
2.30 Leveraging Cell-Free Protein Synthesis for Site-Specific Conjugation to Enhance ADC Therapeutic Index • Introducing cell-free protein synthesis platform leveraging non-natural amino acids for precise conjugation • Engineering ADC to improve safety and widen the therapeutic index of STRO-003 and STRO-004 • Exploring next generation ADCs to overcome drug resistance and maximize efficacy **Gang Yin**, Vice President, Research, **Sutro Biopharma**	**2.30 Highlighting Discovery & Non-Clinical Development of EGFR-B7H3 Bispecific ADC** • Introducing conjugation technology for EGFR-B7H3 targeted bispecific ADC • Detailing data from *in vivo* studies for discovery and mechanistic insights • Exploring ongoing clinical development and highlighting future bispecific ADC development **Kaijie He**, Vice President, Head of Cancer Biology & ADC, **Innovent Biologics**	**2.30 Translational Strategies Towards the Derivation of a Therapeutic Index for Early ADCs** • Discussion and cross-comparison of methodologies towards the projection of efficacious ADC doses • Anticipating ADC tolerability in the clinic: translational considerations and strategy • Learnings to be leveraged for better ADC design **Christina Vasalou**, Director, Head of ADC Translational PKPD, **AstraZeneca**	**2.30 Development of MYTX-011, a cMET ADC: Initial Dose Escalation Results from Phase 1 KisMET-01 Study** • Reviewing the pre-clinical profile of MYTX-011 • Sharing the clinical development status of MYTX-011 • Discussing future developments of MYTX-011 **Gilles Gallant**, Chief Development Officer, **Mythic Therapeutics**	**2.30 Characterizing ADC Positional Isomers to Achieve a Deeper Understanding of ADC Products** • Developing a simple online LC/MS method to characterize ADC positional isomers • Showcasing results of ADC positional isomer characterization • Utilizing methodology to support ADC conjugation process optimization **Zhengqi Zhang**, Senior Scientist, **Merck & Co**	**2.30 Assessing Drug-Linker Manufacturing & Supply to Ensure Upfront Development Under Accelerated IND Timelines** • Drug-linker manufacturing for novel compound is often on the critical path to FIH material delivery • Explaining chemical and analytical process development-research chemistry communication to enable acceleration of IND timeline • Leveraging CDMO networks to shorten tech transfer and manufacturing timeline to achieve candidate selection to IND submission for ADC in 25-28 months **Candice Wong**, Senior Director, Engineering & External Process Development, **Pfizer**
3.00 Targeting TYRP-1 in Malignant Melanoma: Novel mavg-MMAU Linker-Payload Improves Both Efficacy & Tolerability of Auristatin ADCs • TYRP-1 is a novel ADC target for malignant melanoma • Hydrophilic and potent auristatin payload MMAU was superior to topo 1 and topo 2 inhibitors as an anti-TYRP-1 ADC payload • Novel mavg-MMAU linker-payload with high systemic and metabolic stability had superior therapeutic window compared to vedotin • DAR4 and DAR8 mavg-MMAU ADCs are being developed against solid and heme malignancies **Juhani Saarinen**, Chief Executive Officer, **Glykos Finland Oy**	**3.00 A Translational Approach to ADC Evaluation: From *In Vitro* Organoids to Advanced *In Vivo* Models** • Exploring the assessment of ADC efficacy through single-mouse *in vitro* PDXO, MiniPDX, PDX, and clinical MiniPDX models • Demonstrating how these models bridge preclinical findings to clinical indications, offering insights into drug efficacy and resistance • Highlighting the integration of diverse models to accelerate ADC development and guide decision-making in pharmaceutical R&D **Simon Jiang**, Vice President, Biology, **Lide Biotech**	**3.00 Next-Generation Bioconjugate Therapeutics: Driving Innovation with Revolutionary Conjugation Technologies** • Overviewing GeneQuantum's holistic conjugation and manufacturing platforms: iLDC and iGDC • Introducing the world's first rapid ADC screening system: iScreener • Empowering best-in-class and first-in-class XDC therapeutic development through GeneQuantum's leading platform **Paul Song**, Chief Scientific Officer, **GeneQuantum Healthcare**	**3.00 Advantages of Clinical-Stage GlycoConnect™ Platform Technology – Successful Application for Multiple Targets & with Different Payload Classes** • GlycoConnect™, HydraSpace® and toxSYN® technologies enable ADCs with best-in-class therapeutic index potential • Updates on the rapidly advancing pipeline of GlycoConnect™ ADCs by partners • Clinical development insights on the most advanced assets **Anette Sommer**, Head of Biochemistry, **Synaffix**	**3.00 Leveraging Orthogonal icIEF-UV/MS & LC-MS Workflows for Comprehensive Characterization of Antibody-Drug Conjugates** • Combining the power of orthogonal icIEF-UV/MS, native mass spectrometry and electron-activated dissociation (EAD)-based peptide mapping workflows • Applying workflows for high-resolution separation and sensitive detection of charge variants, accurate mass measurement, rapid DAR determination and confident PTM or payload localization using a single MS platform and data processing software **Haichuan Liu, Manager**, Strategic Marketing, Protein Characterization, **SCIEX**	**3.00 ProveoTM, an Integrated Supply Chain for ADCs: From Development to Commercial Manufacturing** • Supply chain integration for the manufacturing of ADCs • Accelerating development of ADCs • Minimizing risks from a CDMO perspective **Vitor Sousa**, Director, Business Development, **Proveo**

CONTENTS

Scientific Program Day One | Tuesday, November 5, 2024

3.30 Afternoon Break & Technology Slam

As you enjoy your afternoon refreshments, you will also have the chance to **be face-to-face with the field's most innovative and exciting technology** and **service providers**. Join the technology slam to hear back-to-back presentations from Beacon, Quantum-Si, and Sony to help identify your next ADC technology provider.

What Makes a Clinically Effective ADC? Breaking Down Recent ADC Clinical Performance

4.30 Technical Excellence in Development & Manufacturing of BioConjugates

- Introduction of the techniques used during development to achieve deep process understanding and right first time transfer to manufacturing
- Exploring the established roadmap to scale up at an experienced ADC manufacturer
- Learning through case studies: seamless transfers from process and analytical development to GMP production

Gary Conway
Principal Production Scientist, GMP Manufacturing
MilliporeSigma

Yomadis Ortiz
Manager, Process & Analytical Development
MilliporeSigma

5.00 Exploring Learnings From Translational & Clinical Development of Dolaflexin & Dolasynthen ADCs

- Contrasting and sharing pre-clinical and clinical data for Dolaflexin and Dolasynthen ADCs, employing the same payload and same antibody
- Predicting and evaluating differences in clinical efficacy and tolerability performance based on preclinical data – what are the core lessons?
- Breaking down how differences in ADC design impact clinical performance

Timothy Lowinger
Chief Science & Technology Officer
Mersana Therapeutics

5.30 Accelerating Novel ADC Development through WuXi XDC's Innovative Technology & Integrated Development/Manufacturing Platform

- Learning how 5 of 13 approved ADCs use random cysteine conjugation with MMAE, capped at 2 mg/kg to avoid TEAEs
- Discussing how WuXiDAR4's proprietary technology creates ADCs with a narrowly distributed DAR for enhanced efficacy and safety, eliminating the need to modify monoclonal antibodies or any enzymes, simplifying the process and reducing costs of goods
- Outlining how WuXi XDC CDMO platform integrates the development and manufacturing of monoclonal antibody intermediates, payload linkers, conjugation, and drug products, expediting development from DNA to IND in under 15 months with over 60 successful IND submissions
- Leveraging deep expertise and comprehensive manufacturing, WuXi XDC offers a clear strategy to secure successful BLA filings for its clients

Marie Zhu
Chief Technology Officer
WuXi XDC

6.00 Reflecting On Phase I Termination of DHES0815A: What Were the Core Lessons Learned?

- Breaking down ADC design, preclinical development, and phase I clinical trial results
- What were the main takeaways from observed clinical toxicities?
- Striving for transparency on ADC clinical trial results regardless of outcome

Gail Lewis
Senior Principal Scientist
Genentech

6.30 Chair's Closing Remarks

Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics

6.30 Scientific Poster Session & Drinks Reception

This is a great opportunity to showcase your latest work and get face-to-face time with attending audience of ADC experts, as well as finding out insights from ongoing ADC development by your peers. In an informal setting, you will be able to discuss, debate, and display your work in the field while enjoying a drink of your choice at our dedicated drinks reception.

Hosted By:
AsymBio 凯莱英生物

7.30 End of Scientific Program Day One

Scientific Program Day Two | Wednesday, November 6, 2024

7.15 **Check In, Morning Coffee & Refreshments**

7.15 **Breakfast Briefing: Sartoflow® Expert SU for Streamlined ADC Manufacturing in Pilot Scale** SARTORIUS

Paul Marks
Product Specialist, TFF
Sartorius

8.10 **Chair's Opening Remarks**

Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics

Showcasing Cutting-Edge Successes of ADC Combinations Reshaping Frontline Treatments in Oncology

8.15 **Breaking Down the Success from the Padcev-Keytruda Combination & Applying Learnings to Future ADC-Immunotherapy Combinations**

- Highlighting safety and clinical outcome readouts from the Phase III combination trial in bladder cancer
- Breaking down strategy, rationale, partnering, and lessons learned advancing through preclinical and clinical strategies
- Evaluating the future of ADC-immunotherapy and other novel combinations with ADCs to redefine patient experience and standard of care

Ahsan Arozullah
Senior Vice President, Head of Oncology Development
Astellas

8.45 **Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology**

- AJICAP® Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
- AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
- Showcasing Bispecific and Trispecific antibodies produced by fully-chemical conjugation technology

Tomohiro Fujii
ADC researcher
Ajinomoto Biopharma Services

9.15 **Trodelvy-Immunotherapy Combinations In Solid Tumors: Rationale & Emerging Data**

- Recapping and contextualizing recent data from Phase II EVOKE-02 trial of Troveldy-Keytruda combinations in lung cancer
- Evaluating rationale and design of Trodelvy-immunotherapy combinations in other solid tumors
- Breaking down the potential – what are the route forward and potential of novel ADC-immunotherapy combinations?

Bilal Piperdi
Vice President, Clinical Development Oncology
Gilead Sciences

9.45 **A Reliable & Flexible Technology for the Rapid Conjugation of Antibodies & Other Biologics**

- Describing how Singzyme provides a one-stop solution for antibodies and nanobodies engineering and conjugation
- Exploring how Singzyme's technology accelerates the development of cancer immunotherapy, allowing faster production of antibody-drug-conjugates with minimal footprint on the final product and the possibility to attach two payloads with a defined DAR
- Exploring Singzyme's technology which allows imaging for disease diagnosis: production of radiopharmaceuticals for PET scan imaging (Nanobodies or mAbs) with minimal radioactive waste thanks to the highest conjugation efficiency on the market

Abbas El Sahili
Chief Executive Officer
Singzyme

10.15 **Accelerated Pathway from Antibody to ADC: Chemistry Matters**

- The pathway from antibody to ADC is complex, resource intensive, and time-consuming
- There are numerous platform-based solutions including various payload classes, differing linker chemistries, and conjugation technologies to evaluate
- This talk will demonstrate how having high-quality material, expertise and the right technology can accelerate your ADC programs

Naresh Jain
Chief Executive Officer
NJ Bio

10.30 **Morning Break & Networking**

Reconnect with your fellow members of the ADC community to forge new relationships and break down your key takeaways from the first main conference day. If you didn't the chance to see all the scientific posters on Tuesday, a select few will still be available so make sure to speak to all the presenters!

Scientific Program Day Two | Wednesday, November 6, 2024

15th ANNUAL WORLD adc SAN DIEGO 2024

Discovery Chemistry	Cellular Biology	Translational	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain
	Chair: Gail Lewis, Senior Principal Scientist, **Genentech**	**Chair: Rakesh Dixit**, President & Chief Executive Officer, **Bionavigen Oncology**	**Chair: Patrick Zweidler-McKay**, Former Executive Medical Director, **ImmunoGen**	**Chair: Srinath Thirumalairajan**, Director, Process Engineering, **Pfizer**	**Chair: Radhika Balasubramani,** Director, Technical Product Steward, Antibody Drug Conjugates, **Merck**
Diving Into Innovations in ADC Linker-Payload Chemistry for Next Generation ADC Development	**Showcasing ADC Development & Rationale Against Up & Coming Tumor Targets**	**Exploring Preclinical Model Selection & Minimizing ADC Translation Mismatch**	**Evaluating Dose Escalation & Optimization in ADC Clinical Development**	**Streamlining & Understanding Conjugation Process & Manufacturing**	**Ensuring Process Understanding for Efficient Tech Transfer & External Manufacturing**
11.30 **Harnessing AbClick Pro for AT-211 Yields a CLDN 18.2 Targeting ADC with Superior Therapeutic Index Among Comparable ADCs** • Introducing AbClick, a site-selective cross-linker technology targeting ϵ-NH2 group of K248 in human IgG1s • Applying technology to develop a anti-claudin 18.2 ADC with inhibitor MMAE and consistent DAR 2 • Explaining superior *in vitro* and *in vivo* efficacy, toxicity and xenograft mouse model dosing for improved safety with site-selective and stable ADC linker technologies **Sang Jeon Chung**, Chief Scientific Officer, **AbTis**	11.30 **Showcasing Advantages From Next Generation ISAC Development** • Showcasing development of Next Generation ISACs with enhanced potency • Explaining Next Generation ISACs enabling targeting of tumors with lower antigen expression • Applying learnings from BDC-1001 to development of Next Generation ISACS, including targeting of CEA and Claudin 18.2 **Shelley Ackerman**, Senior Director & Program Team Lead, **Bolt Biotherapeutics**	11.30 **Bridging Preclinical Models & Clinical Success: Leveraging PDOs & RWD to Advance ADC Development** • Applying RWD to identify novel therapeutic targets and provide insights into responder populations for ADC development • Examining how patient-derived organoids can enhance biomarker validation and help guide therapeutic decisions • Highlighting a "lab-in-the-loop" approach to incorporate screening panels of PDOs – optimized for ADC evaluation – and RWD to enhance biomarker validation and guide pipeline prioritization **Tim Hagerty**, Vice President, Life Science Strategy, **Tempus** **Richard Klinghoffer**, Senior Vice President, Head of Systems Biology, **Tempus**	11.30 **Analyzing the ADC Boom** • Exploring trends and updates from late preclinical to early clinical ADC development • Reviewing key highlights and updates for ADC development in 2024 • Presenting an update on the key movement of drugs in early clinical development • Showcasing an at-a-glance summary of preclinical drugs approaching first-in-human trials **Jake Morris,** Senior Account Manager & ADC Insights Lead, **Beacon**	11.30 **Leveraging ADC Development Knowledge to Overcome Challenges & Build Opportunities for the Efficient Scale-up & Development of Novel AOC's** • Navigating the nuances of oligonucleotide conjugate process development • Understanding how to leverage the physiochemical properties between different types of AOCs **Stephen Verespy**, Scientific Leader, **Abzena**	11.30 **Implementing Practical Flash Chromatography for Clinical ADC Payload-Linker Production** • Breaking down the principles of liquid chromatography • Showcasing equipment for development and scale-up of flash chromatography • Developing practical purifications for clinical GMP production **William Sanders**, Global Vice President, Chemical Development Operations, **Veranova**
12.00 **HDP-201, a Multimeric Linker-Exatecan-based ADC as Novel Therapeutic Modality for Treatment of Solid Tumors** • Showcasing HDP-201 with multimeric linker-exatecan payload • Outlining how the use of solubility enhancers to facilitate site-specific coupling to cysteines resulted in a stable, potent, and well tolerated ADC • Assessing dose-dependent tumor regression *in vivo* and improved anti-tumor efficacy after multiple dosing **Andreas Pahl**, Chief Executive Officer, **Heidelberg Pharma**	12.00 **Investigating Preclinical Development of AGX101, a TM4SF1-directed ADC that Attacks Tumor Vasculature** • Learn about TM4SF1 biology and its attractiveness as an oncology target • Review the advantages of attacking the tumor vasculature • Preclinical evaluation of AGX101, the first TM4SF1-directed ADC to reach the clinic **Paul Jaminet,** Founder & Chief Executive Officer, **Angiex**	12.00 **Improving the Predictive Value of Preclinical & Non-Clinical Work to Aid Successful Clinical Development** • How well can non-clinical animal study findings translate into humans? • Reapproaching the way we use animal models for preclinical investigation • Increasing translational value and success into the clinic • Learning from the clinical successes and failures of ADCs: case study of HER2 targeting ADCs **Rakesh Dixit**, President & Chief Executive Officer, **Bionavigen Oncology**	12.00 **Exploring Dose Escalation of AMT-116 To Maximize the Therapeutic Window in the Clinic** • Exploring novel target expression and evaluating target profile ac ross multiple indications • Outlining early clinical readouts from early clinical work and dose escalation • Exploring ADC design and including T-moiety linker technology, to maximize the therapeutic window for widely expressed targets **Shu-Hui Liu,** Chief Scientific Officer, **Multitude Therapeutics**	12.00 **Increasing Product Quality & Yield by Selective Reduction & Conjugation Processes for Site-Specific & Wild-type Antibodies** • Exploring how the selective reduction and conjugation method was developed to increase product quality, yield, and process simplification for site-specific ADCs • Discussing how the method can be further used to enrich desired DAR species and increase yield from wild-type antibodies • Reviewing considerations from other process steps play roles in process robustness and product quality control **Xiaoli Liao,** Principal Scientist II, Operations S&T & Process R&D, **AbbVie**	12.00 **Navigating Efficient ADC Process & Technology Transfer During Scale Up** • Carrying out process characterization and technology transfer to ADC manufacturing sites • Bridging process development and research teams with manufacturing plants • Undergoing testing and characterization to ensure robust process for manufacturing **Philip Kuhl**, Distinguished Scientist, Bioconjugation & Chemistry Commercialization, **Merck & Co**

CONTENTS

Scientific Program Day Two | Wednesday, November 6, 2024

Discovery Chemistry

12.30 Showcasing NMS's Portfolio of Cytotoxins & Targeted Payloads to Drive ADC Innovation

- Overviewing NMS portfolio of innovative payload linkers with diversified mechanisms of action
- Exploring preclinical evaluation of duocarmycin, next generation anthracycline, and targeted payloads tailored to effectively target hard-to-treat cancers even in chemoresistant settings with enhanced specificity
- Outlining NMS fully integrated approach to deliver unparalleled ADC development opportunities with enhanced efficacy and safety

Barbara Valsasina, ADC Portfolio Head, **Nerviano Medical Sciences**

12.45 Click Chemistry Enabled Pre-targeting as a Solution to Target Independent ADC Toxicities

- Introducing Shasqi's Click Activated Protodrugs Against Cancer (CAPAC)
- Discussing how the design features of CAPAC allow the platform to overcome efficacy limiting toxicities associated with ADCs
- Reviewing preclinical safety and efficacy data from Shasqi's pipeline assets

Jose Mejia Oneto, Founder & Chief Executive Officer, **Shasqi**

Cellular Biology

12.30 Internalizing Fully Human Therapeutic Antibody Development in 60 Days

- Developing proprietary technology allowing a rapid fully human therapeutic antibody development against your ADC targets in about 60 days
- Learning how based on our past record, > 20% of the clones produced antibody against the target
- Identifying neutralizing, internalizing and agonistic IgG antibodies with varying affinities (KD: 10-8 ~ 10-12 M)

Jun Hayashi, President, **Precision Antibody**

12.45 Intelligent Design of Bispecific & Biparatopic ADCs Using High-Throughput Single-Cell Functional Screening

- Overview of Aureka's biologics discovery platform that leverages autonomous evolution, high-throughput function screening, and AI *de novo* design models
- Co-encapsulation of antibody cell library with reporter cell for high-throughput internalization functional screening
- Showcase iterative design, test, and optimize cycles to design optimal bispecific and biparatopic ADCs

Jenny Hunt, Director, Corporate Alliances, **Aureka Biotechnologies**

Translational

12.30 Discovery & Preclinical Validation of a Novel Enzyme Cleavable Linker for Development of Next-Generation ADC Against Solid Tumors

- Outline how heterogeneity and poor drug penetration of solid tumors is a current challenge for novel ADC development
- Discuss how Nona Biosciences tried to address this challenge using a novel linker that is cleaved by a unique enzyme in the TME
- Assess *in vitro* and *in vivo* studies of this novel linker-payload show superior efficacy and safety

Musheng Bao, Vice President, Head of Biology, **Nona Biosciences**

Clinical Lessons

12.30 Circulating Tumor DNA (ctDNA) to Identify High-Risk Populations & Predict Therapy Efficacy

- Discover how ctDNA can identify high-risk patients with molecular residual disease likely to relapse without further treatment, emphasizing the need for more interventional trials, including with ADCs, for these populations
- Review changes in ctDNA levels can serve as early efficacy or pharmacodynamic markers, predicting therapy response as early as 6 weeks
- Discuss how Signatera is the most extensively validated, widely used, and broadly reimbursed ctDNA MRD assay, enabling patient stratification and treatment response monitoring to accelerate clinical development, currently used prospectively in over 20 ongoing clinical trials

Vikki Cerniglia, Senior Director, Biopharma Partnerships, **Natera**

Process & Analytical Development

12.30 Streamlining ADC Development & Manufacturing Journey With Samsung Biologics

- Discussing Samsung Biologics' strategic service expansion into ADCs, leveraging mAb development and manufacturing expertise
- Optimizing ADC facility design and readiness to ensure operational excellence
- Streamlining ADC process development through fundamental principles and effective tech transfer methodologies
- Maximizing program potential through technical expertise in conjugation, analytical methods, formulation, and lyophilization

Joseph Jeong, Vice President, ADC Development Team, **Samsung Biologics**

Manufacturing & Supply Chain

12.30 Accelerating the Development of ADCs by Fully Integrated Capabilities

- ADC development and manufacturing requires developers to possess or have access to the R&D and manufacturing capabilities in mAb, payload-linkers, and conjugation technologies
- Introducing a flexible and diversified ADC service platform covering all ADC components needed for the development and manufacturing
- Exploring case studies of fully integrated ADC CMC development strategy, empowered our in-house team and facilities, can deliver DNA-to-IND filing timeline within 13-15 months of DNA transfection

Weibin Chen, Head of Analytical Chemistry, **AsymBio**



"ADCs are essential tools to improve outcome in patients with cancers. World ADC is a premier congress where the future of ADCs as a class and the role for potential combinations to keep the field moving forward will be discussed"

Gilead Sciences

1.00 Lunch & Learn Presented By cytiva

CONTENTS

Scientific Program Day Two | Wednesday, November 6, 2024

Discovery Chemistry	Cellular Biology	Translational	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain
Maximizing ADC Discovery Characterization to Bring Clinical Benefit	**Leveraging Biology & Omics Tools for ADC Target Discovery**	**Tackling Characterization of Novel Payloads & Linkers to Maximize Translation**	**Breaking Down the Assumptions: What Makes a Clinically Effective ADC?**	**Ensuring Conjugation & Drug-Linker Quality Throughout ADC Process Development**	**Understanding Best ADC Manufacturing Practices Under Tight Manufacturing Timelines**
2.00 **Showcasing the T-Moiety Linker Platform to Expand Payloads Used in ADCs** • Introducing T-Moiety linker technology and MabArray target discovery system to develop ADCs against first-in-class HER-3, TF and FIC targets • Leveraging linker technology to work with hydrophobic payloads and expand the therapeutic window of ADCs in development • Applying novel linker technology to known exatecan payloads **Xiaona Jing,** Senior Vice President, Global Product Development & Partnering, **Multitude Therapeutics**	2.00 **Leveraging OGAP® Target Discovery Platform for Novel Target Identification & First-In-Class ADC Development** • Developing OBT's quantitative membrane tissue proteomics from cancer patient tissue biopsies to discover new therapeutic targets • Assessing the advantages of directly determining protein abundance and variant in patients' tissues • Reviewing the patient need for new ADC drug targets and how OGAP facilitates first-in-class drug development **Yu-Tzu Tai**, Associate Director, ADC & Translational Research, **Oxford BioTherapeutics**	2.00 **Showcasing Development of a Second Generation Anti-Ly6E ADC** • Outlining Anti-Ly6E MMAE conjugates evidence of clinical activity but poor durability of response with hints of ABC transporter-driven resistance • Developing novel DNA-crosslinking payloads resistant to export with enhanced activity in multiple *in vivo* models • Using virus-like particles to display Ly6E enabled discovery of a substantially more active antibodies *in vitro* and *in vivo* **Nicolas Agard**, Senior Principal Scientist, **Genentech**	2.00 **Encouraging Clinical Efficacy & Safety Data of DB1303 & DB1305 from Phase1/2 studies** • Introduction of Duality DITAC platform with expanded therapeutic window • Highlighting the early clinical efficacy and safety data from DB1303 (HER2 ADC) and DB1305 (Trop2 ADC) from DITAC platform • Review combination strategy of developing HER2 ADC and TROP2 ADC **Yang Qiu,** Chief Scientific Officer, **Duality Biologics**	2.00 **ADC Conjugation Process Optimization: Enhancing Homogeneity & Reducing Mis-Bridged Species** • Disulfide bond rebridging represents an innovative conjugation technology for homogeneous ADCs • Explaining challenges with quantity of mis-bridged species and half-antibody conjugates • Optimizing conjugation process to reduce the half-antibody conjugates from >50% to <30% while maintaining target DAR **Mimi Zhu,** Senior Manager, Downstream Process Development & Operations, **GSK**	2.00 **Deep Diving Into ADC Drug Product Development & Manufacturing Challenges, & Mitigation Strategies** • Reviewing commercial ADC formulation and dosage forms • Breaking down early-stage ADC drug product manufacturing • Assessing the unique challenges and mitigation strategies for drug product development and manufacturing **Bowen Jiang**, Senior Research Scientist I, Bio Formulation & Process Development, **Gilead Sciences**
2.30 **Breaking Down the Foresight During Discovery to Maximize Impact in the Clinic** • Introducing next generation conditionally active ADCs • Investigating tumor analysis to predict clinical benefit • Outlining linker selection for improved activity **Gerhard Frey,** Vice President, Technology Development, **BioAtla**	2.30 **Roundtable Discussion: What Are the Characteristics for "Clean" ADC Targets With the Most Promise?** • Outlining the characteristics for clean ADC Targets to identify targets with most promise • Breaking down the growing toolkit for target discovery and debating how to best apply methodologies • Breaking down workflows and challenges to progress from target discovery to target validation **Cellular Biology Track Closes**	2.30 **Characterizing & Forecasting Translational Success of Novel ADC Linkers** • Outlining Genmab's approach to ADC design and pipeline • Showcasing preclinical data for novel ADC linker-drugs • Evaluating translational success of design concepts into clinical trials **Zhu Chen**, Senior Vice President & Head, ADC Center of Excellence, **Genmab**	2.30 **Contextualizing Clinical Development of CBP-1008 Bi-XDC in Ovarian Cancer** • Showcasing promising safety and efficacy performance of Bi-XDC CBP-1008 • Exploring CBP-1008 performance in platinum resistant ovarian cancer patients • Evaluating Bi-XDC proof of concept development through CBP-1018 and 1019 **Mo Xu**, Chief Medical Officer, **Coherent Pharma**	2.30 **Outlining Holistic ADC Drug-Linker Development Through Downstream Conjugation Team Collaboration** • Signifying the need to collaborate between drug-linker and conjugation development teams • Overviewing how the two teams work closely to trouble-shoot and assess downstream impact of drug-linker impurities • Overviewing case study examples of the collaboration work involved **Srinath Thirumalairajan**, Director, Process Engineering, **Pfizer**	2.30 **Roundtable Discussion: Navigating Manufacturing Timelines' Pressure in a Competitive ADC Landscape** • Assessing rate-limiting hurdles in ADC development and manufacturing under accelerated IND and BLA submission timelines • Utilizing real-time experimental data to take on calculated risk and parallel development • Optimizing end to end internal alignment to ensure ADC supply chain efficiency **Manufacturing & Supply Chain Track Closes**

Scientific Program Day Two | Wednesday, November 6, 2024

Discovery Chemistry	Translational	Clinical Lessons	Process & Analytical Development
3:00 Optimizing High DAR & Dual Payload ADCs: Discovery of Hydrophilic β-Glu Cleavable Linker Payloads for Superior Efficacy & Safety • Exploring novel linker-payload attributes that improve safety and therapeutic index of site-specific ADCs • Emphasizing the High DAR ADCs with novel linker technology for deeper response • Discussing the synergetic efficacy of Topo1 inhibitor ADCs in combination with diverse MoA class of payloads to overcome the resistance **Krishna Bajjuri,** Senior Director, Chemistry, **Sutro Biopharma**	**3.00 Exploring Novel ADC Platforms to Reimagine ADC From Concept to Clinical Success** • Evaluating lessons learned from the clinical success of ADCs, including assessing how clinically meaningful biomarkers can influence patient selection and clinical trial design • Assessing how linker design impacts ADC performance • Exploring GlycOBI®, a site-specific glycan conjugation platform, to enhance ADC performance **David Huang**, Director, Medicinal Chemistry, **OBI Pharma**	**3:00 Breaking Down Class: Examples of ADC Efficacy & Safety in the Clinic** • Looking across the ADC landscape to examine predictiveness of early clinical data on outcome • Deploying a clinical analytics framework to identify and evaluate fit-for-size ADC partnering opportunities **Jon Travers,** Senior Director, External Innovation & Early Development, **Ipsen**	**3.00 Roundtable Session: Breaking Down the Top Opportunities to Overcome ADC Process & Analytical Development Challenges** Join this closing roundtable session with leaders in ADC process and analytical development field to break down the key learnings from the past two days presentations. With your fellow speakers and attendees, discuss, debate and evaluate the opportunities and challenges in characterization of complex ADC molecules, identifying and controlling impurities, and ADC process optimization

3.30 Afternoon Break & Networking

BCMA Breakdown: Exploring Case Studies of ADC Development for Targets Without an Approved Therapy

4.00 ATACs: A New Payload Provides New Options for Cancer Therapy

- Discussing a payload with a new mode of action providing new options to fight cancer
- Understanding how the ATAC platform optimized the ADC technology for that unique payload
- Clinical update on HDP-101 targeting BCMA; the first ATAC which is now in dose escalation in myeloma patients

Torsten Hechler
Senior Vice President, ADC Research
Heidelberg Pharma

4.30 Tubulis – Pushing the Boundaries of ADCs

- Advancing multiple ADC programs into the clinic, based on its novel Tubutecan linker-payload system to enable optimized, sustained on-tumor Topo-1 payload delivery
- In discovery, developing a novel linker component (Alco5) to broadly unlock novel ADC payload strategies
- Specifically and based on the platform versatility, systematically exploring degrader-based payloads to broaden the scope of intracellular payload targets

Dominik Schumacher
Chief Executive Officer
Tubulis

CONTENTS

5:00 **Contextualizing the Clinical Journey of Belantamab Mafodotin as a BCMA Targeting ADC in Treatment of Relapsed or Refractory Multiple Myeloma**

- Exploring preclinical evidence of Belantamab Mafodotin's underlying mechanism of action in support of monotherapy development and rationale for synergy in combination
- Breaking down the clinical journey from statistically negative DREAMM-3 monotherapy readout to positive combination therapy data with DREAMM-7 and DREAMM-8
- Explaining the regulatory vs. clinical journey to better understand strength of evidence of Belantamab Mafodotin as a monotherapy and in combinations

Pralay Mukhopadhyay
Vice President, Medicine Development Leader, Oncology R&D
GSK

5:30 **Chair's Closing Remarks**

Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics

6:00 11th World ADC Awards

Celebrating 11 Years of Recognizing the Top Caliber, Achievement & Influence in ADC Development

At the end of the main conference days, join us for an unforgettable evening honoring the best companies, teams, programs, and individuals in the ADC field.

Across 10 categories, this is your opportunity to recognize the amazing individual, project, and company-wide creativity, innovation, leadership, and devotion made by your peers over the past 12 months. Make sure you have your say and nominate your favorite contributors that have propelled ADCs to be biopharma's hottest therapeutic modality at the forefront oncology R&D and dealmaking, and those working towards making ADCs standard of care treatments in oncology and beyond.

Award Categories

- Best ADC Platform Technology
- Best New Drug Developer
- Most Promising Clinical Candidate
- Best Contract Manufacturing (CDMO) Provider
- Best Contract Research (CRO) Provider
- Best ADC Preclinical Publication 2023
- Best ADC Clinical Publication 2023
- Outstanding Academic Investigator Award
- The George R. Pettit Individual Input to the Field 2023
- Long Standing Contribution to the Field

11th ANNUAL WORLD adc AWARDS

In Partnership With:

AMBRX Johnson & Johnson

Find out more:
www.worldadc-awards.com

8:00 **End of Scientific Program Day Two**

Post-Conference Workshop Day | Thursday, November 7, 2024

15th ANNUAL WORLD adc SAN DIEGO 2024

8.00 Check In, Morning Coffee & Refreshments

9.00 - Morning Sessions

For Beginners in the ADC Field

Whether you are brand-new to the ADC space or keen to expand your knowledge into novel areas of development, these deep-diving, three hour collaborative sessions spanning **ADC discovery chemistry innovation**, **preclinical**, **and clinical optimization of the therapeutic index**, **immune-stimulating ADCs**, and **ADC analytical strategy** will provide the a necessary foundation blending takeaways from past ADC development in addition to new and exciting learnings.

For Everyone in the ADC Field

Applicable across all levels of ADC expertise and experience, join your peers in the field to zoom into key questions regarding **ADC design and putting the why behind clinical performance, computational ADC design methodologies, complex ADC impurity characterization**, **and regulatory CMC strategy**.

Workshop A

The Chemistry & Properties of Antibody-Drug Conjugates: Linkers, Toxins & Their Effect on Therapeutic Index

Understanding the innovation, opportunities and challenges at the forefront of ADC discovery chemistry is vital to optimize ADC design from the get-go. Join this workshop session to secure your understanding of fundamental principles and practices of ADC linker, payload and conjugation chemistries.

Workshop highlights include:

- Overviewing different classes of payloads and linker technologies employed by ADCs
- Analyzing the synthetic challenges in preparation of linker-payload constructs and reactive groups necessary for attachment and release
- Discussing the pros and cons of existing conjugation technologies

Julien Dugal-Tessier, President & Chief Scientific Officer, **NJ Bio**

Workshop B

Optimizing the Translational Aspects of ADC Efficacy, Safety & Therapeutic Index

ADC development continues to face the translational barrier to preclinical activity not matching early clinical safety and efficacy readouts. Attend this workshop to best understand preclinical development and rationale to effectively characterize ADC safety and efficacy to minimize the mismatch once you enter clinical investigation.

Workshop highlights include:

- Breaking down on and off-target ADCs toxicities and exploring mitigation strategies in preclinical and clinical scenarios
- Minimizing the translational mismatch between animal studies and clinical trials
- Balancing ADC efficacy and safety to maximize the therapeutic index

Rakesh Dixit, President & Chief Executive Officer, **Bionavigen Oncology**

Workshop B Timings: 10:15am - 12:15pm

Workshop C

Immune-Stimulating Payloads: Exploring Potential & Applications in ADCs

As ADCs have demonstrated their potential to become new standard of treatments in oncology, the innovation and development of ADC therapies has expanded to new mechanisms as well as indications beyond oncology. Join this workshop to delve into ADC development of immune-stimulating ADCs for applications in oncology and beyond.

Workshop highlights include:

- Breaking down the potential and additional challenges for expanding ADC development into indications beyond oncology
- Introducing platform development of inhibitor payloads to develop immune-stimulating ADCs
- Delving into novel payload classes to stimulate T-cells in the tumor microenvironment
- Exploring ADC targeting beyond tumor cells for applications outside oncology

James Palacino, Head, Research, **Orum Therapeutics**

Joanne Lim, Associate Director, Immunology, **Orum Therapeutics**

Teresa Mako, Scientist I, Medicinal Chemistry, **Orum Therapeutics**

L. Nathan Tumey, Associate Professor, **Binghampton University**

Workshop D

Breaking Down Different ADC Design & Component Contributions to Set Up ADC Development for Success

As more ADCs containing different payloads and linkers are developed to tackle different targets, understanding different design and synergistic component contributions to ADC activity is fundamental to set up your ADC development for success. Join this session to contextualize the performance of different ADC designs and set up for ADC development for success.

Workshop highlights include:

- Showcasing ADC case studies and designs tackling the same target - are there multiple pathways and designs to achieve success against the same targets?
- Breaking down insights gained from recent ADC clinical trials
- Characterizing individual competent contributions as well as how all component work as a whole
- Debating the valuable takeaways from different approaches to the same target

Robert Lutz, Chief Scientific Officer, **Iksuda Therapeutics**

Jutta Deckert, Vice President, Research & Development, **Iksuda Therapeutics**

Workshop E

Discussing Control Strategy, Purge Factors & Regulatory Findings for Antibody-Drug Conjugates

The complex synthesis process of drug-linker manufacturing and conjugation stages opens the door for ADC impurities that are difficult to identify and control. Join this workshop led by big pharma leaders and members of the IQ consortium to investigate the playbook for ADC impurity process and control strategy.

Workshop highlights include:

- Breaking down the end-to-end playbook for drug-linker CMC development including: specifications and impurity control strategy, comparability, process development and validation, stability, and post-approval changes
- Delving into framework for purge factor calculations and experimental evaluation of clearance of small molecule impurities in the ADC drug substance manufacturing process
- Exploring ADC IND and BLA filing strategies and recommendations per the ICH M4Q (R2) framework

Seb Caille, Scientific Director, Process Development, **Amgen**

Llorente Bonaga, Senior Director, Global Regulatory Affairs & Clinical Safety, CMC, **Merck & Co**

Srinath Thirumalairajan, Director, Process Engineering, **Pfizer**

Post-Conference Workshop Day | Thursday, November 7, 2024

12.00 Lunch & Networking

1.00 - Afternoon Sessions

For Beginners in the ADC Field

Workshop F

1.00 Delving Into the Chemistry & Art of ADC Linkers & Understanding Significance & Applications on ADC Properties & Performance

Acting as the glue between the ADC payload and antibody or equivalent targeting moiety, linkers play a vital role influencing ADC properties and performance. Join this interactive session led by Paul Davis, chemist and ADC activist and inventor of the uniform PEG technology, to deep dive into ADC linker chemistry and applications to improve ADC qualities.

Workshop highlights include:

- Linker chemistry 101: breaking down the current state of the science behind ADC linkers – bringing the chemistry to those designing and intending to design the ADCs
- Contextualizing and processing linker data seen in literature and tackling a uniform linker nomenclature
- Hearing case study examples of best linker technology currently under development and discussing the methodology of assessing performance
- Breaking down the benefits and challenges of how best to leverage these as guidance in your ADC design

Paul Davis, President, **Montgomery Holdings**

David Bramhill, President & Founder, **Bramhill Biologics Consulting**

Charley Wu, Managing Director, **Panlabs Biologics**

Workshop G

1.00 Delving into Strategy & Best Practices to Expand ADC Therapeutic Window in the Clinic

Understanding what makes a clinically effective ADC is crucial to best predict ADC clinical performance. Led by senior experts from companies with market-approved ADCs, join this session to break down clinical development strategy for ADCs to maximize the therapeutic window.

Workshop highlights include:

- Highlighting mitigation strategy case studies to deal with ADC toxicity in early clinical development
- Designing Phase I studies and undergoing dose escalation to align with Project Optimus guidelines
- Collating information to optimize and expand the therapeutic window in the clinic and understand ADC component contributions

Patrick Zweidler-McKay, Former Executive Medical Director, **ImmunoGen**

Gail Lewis, Senior Principal Scientist, **Genentech**

Rakesh Dixit, President & Chief Executive Officer, **Bionavigen Oncology**

Workshop H

1.00 Setting Up Analytical Characterization Strategy for Success Across ADC Development Phases

Robust and detailed analytical characterization is the cornerstone of successful ADC development. Join this workshop to examine core analytical technologies and strategies to best characterize complex ADC molecules across different development phases.

Workshop highlights include:

- Bridging small molecule and biologic characterization knowledge for linker-payload, biologic, and overall conjugate components
- Outlining workflow and considerations for ADC purity, potency, and physiochemical characterization
- Evaluating differences between early and late-phase ADC analytical development

Sarah Kiehna, Director, Biologics Analytical Development, External Programs, **AbbVie**

Linjie Han, Associate Director, CMC Analytical Lead, **AbbVie**

Paul Thomas, Principal Research Scientist II, Biologics Analytical Research & Development, **AbbVie**

For Everyone in the ADC Field

Workshop I

1.00 Using AI & Computational Approaches for Early-Stage Design & Late-Stage Development of Antibody Drug Conjugates

The use of AI, machine learning, and computational approaches provides a powerful opportunity to predict ADC properties and behavior, especially against mismatched readouts between preclinical models and clinical trials. Don't miss this workshop investigating the implementation of simulators to predict how ADC design influences efficacy.

Workshop highlights include:

- Exploring the multiscale mechanisms of ADC distribution, from subcellular to cellular, tissue, organ, and systemic biodistribution
- Investigating AI methods in preclinical and clinical development of ADCs
- Discussing the (sometimes) counterintuitive results of ADC efficacy in animals and the clinic
- Reviewing the practical implementation of an ADC simulator to predict how ADC design impacts efficacy

Greg Thurber, Associate Professor & Chair, Graduate Education, **University of Michigan**

Dowdy Jackson, Chief Executive Officer, **Jackson Consulting Group**

Workshop J

1.00 Blending Regulatory & Biopharma Points of View to Best Understand Regulatory Expectations & Submissions

In a field with accelerated development timelines and limited manufacturing experience ahead of regulatory interactions; putting together the right data package and open communication with regulators is crucial to best navigate ADC regulatory submissions. Join this workshop to unravel the requirements and best practices for ADC late-stage CMC strategy.

Workshop highlights include:

- Preparing for regulatory submissions with tight timelines for process and analytical method validation
- Setting specifications - what are the minimum requirements and regulatory flexibility with limited batches and manufacturing experiences?
- Hearing from regulators: what is the minimum data package vs the nice to have?
- Discussing case study takeaways from regulatory interactions

Dawn Spiller, Senior Director & Group Manager, **AstraZeneca**

Hema Balachandra, Associate Director, Biologics CMC, **Merck & Co**

Karina Zuck, Senior CMC Reviewer, **FDA**

4.00 **End of Post-Conference Workshop Day**

Take the Spotlight: Partner With Us

As ADCs continue to prove they can offer transformative clinical advancements and a surge of new companies enter the field, everyone is looking to find their angle in a market heading for £30 billion in sales by 2028. With sky-high investments maintaining momentum, biopharma's focus remains on identifying innovative technologies and custom services to establish ADCs as the new standard of care treatments in oncology and beyond.

This includes CDMOs with increased capacity and tailored solutions for fast-paced manufacturing timelines, novel linkers, payloads and platform technologies to harness next-generation ADC design, biomarker and diagnostic services to optimize patient selection for ADC precision medicine and toxicity, PK/PD, and pharmacology services to maximize the therapeutic index of their ADCs.

Partner with the 15th World ADC San Diego to:

- **Showcase** your innovative solutions at the world's longest standing and largest gathering of ADC experts spanning discovery, translational, clinical, process and analytical development, and manufacturing expertise, who are actively seeking high level support
- **Stand out** from your competitors in this rapidly expanding and competitive field by demonstrating to prospective clients how your ADC services and technologies can meet their increasing demands
- **Establish** your company at the heart of ADC pharma and biotech dealmaking with bespoke partnership opportunities and make an impact that lasts on biopharma's hottest therapeutic modality

Matt Ashman
Commercial Director
Telephone: +1 617 455 4188
Email: sponsor@hansonwade.com

George Shrimpton
Senior Partnerships Director
Telephone: +1 617 455 4188
Email: sponsor@hansonwade.com

COMPANY TYPE:



- Equipment & Service Providers
- Drug Developers
- Healthcare Providers
- Other

SENIORITY:



- CxO: 14%
- Vice President: 10%
- Director: 29%
- Head/Manager/ Project Leader: 13%
- Scientist: 21%
- Other: 13%

*Statistics taken from the 14th World ADC San Diego

Partnership Opportunities Include:

- Data-driven or Case Study led presentations to position yourself as a thought-leader
- The Tech Slam to showcase your unique technologies
- Expert Panel Inclusion to shape forward-thinking discussions
- Exhibition Booth to raise brand awareness & answer questions from prospect customers
- Organized Networking to generate commercial collaborations
- Exclusive access to the Blind Delegate List to plan your 1-2-1 conversations in advance
- Hosted Lunch, drinks reception, & dinner for exclusive time with your target audience
- On-site & Web Branding to highlight your company at the forefront of this space

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW

Proud to Partner With

Lead Partner: BSP Pharmaceuticals

BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxic characteristics for the Pharmaceuticals Industry. BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high containment plant.

www.bsppharmaceuticals.com

Senior Partner: Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service, trusted partnership and peace of mind you've come to rely on.

www.ajibio-pharma.com

Senior Partner: Ambrx, a J&J Company

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

www.jnj.com

Senior Partner: MilliporeSigma

Millipore Sigma is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life-saving therapies. We have the largest offering of products for formulations, actives, and biotechnology processes. Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers, and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts, and stabilizers and from chromatography to TFF equipment, including single-use templates.

www.sigmaaldrich.com

Senior Partner: NJ Bio, Inc

NJ Bio Inc. is a CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors. Main service areas include antibody drug conjugates, nucleotide and oligonucleotide synthesis, multi-step organic synthesis, PROTAC and flow chemistry based process development.

www.njbio.com

Senior Partner: Singzyme

Singzyme's mission is to deliver on the promise of effective immune-therapies by developing safer and more homogenous, precision medicines for the well-being of patients worldwide. Singzyme applies its platform technology in the field of immune-therapies with a focus on the conjugation of active molecules to protein carriers, for example, but not limited to ADCs

www.singzyme.com

Senior Partner: Tubulis

Reimagining Antibody Drug Conjugates: Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of ADCs by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and will collaborate with partners to usher in a new ADC era and deliver better outcomes for patients.

www.tubulis.com

Senior Partner: WuXi XDC

WuXi XDC Cayman Inc. ("WuXi XDC" , stock code: 2268.HK) is a leading global CRDMO focused on ADCs and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC has been successful in bringing multiple ADC projects to the IND filing stage in 15 months or less, nearly cutting in half the traditional development timeline.

www.wuxixdc.com

2024 Partners & Exhibitors

Program Partners

Exhibition Partners

Event Partners

Ready to Register?

3 Easy Ways To Book

www.worldadc-usa.com/take-part/register

register@hansonwade.com

US +1 415 735 3289

Team Discounts

Get value for money using special team discounts:

- **20% discount – 7+ delegates**
- **15% discount – 5+ delegates**
- **10% discount – 3+ delegates**

Please note that discounts are only valid when 3 or more delegates from one company register at the same time. Not for profit rates are available - email adc@hansonwade.com

Venue

Town & Country San Diego

500 Hotel Circle, North San Diego, CA, 92108

www.towncountry.com

Terms & Conditions

Full payment is due on registration.

Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom.

Top Reasons Not to Miss the *15th World ADC San Diego*

1. **Gain** the latest insights from 140+ experts across discovery, translational, clinical, process and analytical development, and manufacturing content to expose yourself to new innovation in ADC development
2. **Reunite** in person with 1200+ of your peers, both newcomers and long-standing experts solely dedicated to advancing ADCs towards standard of care treatments
3. **Access** innovative and exciting talks on end-to-end ADC development to uncover where the field is heading in 2024 and beyond with the largest and most comprehensive program to date

Drug Developer & Platform Tech Pricing	Register Before the Event Starts	On the Door Price
Conference + Workshop Day & Seminar Day (Full 4 Day Access Pass) MOST POPULAR	$4,897 **(Save $300)**	$5,197
Conference + Workshop Day OR **Conference + Seminar Day** (3 Day Pass)	$3,898 **(Save $200)**	$4,098
Conference Only (2 Day Pass)	$2,899 **(Save $100)**	$2,999

Academic Pricing	Register Before the Event Starts	On the Door Price
Conference + Workshop Day & Seminar Day (Full 4 Day Access Pass)	$4,197 **(Save $300)**	$4,497
Conference + Workshop Day OR **Conference + Seminar Day** (3 Day Pass)	$3,398 **(Save $200)**	$3,598
Conference Only (2 Day Pass)	$2,599 **(Save $100)**	$2,699

Service Provider Pricing	Register Before the Event Starts	On the Door Price
Conference + Workshop Day & Seminar Day (Full 4 Day Access Pass)	$6,497 **(Save $300)**	$6,797
Conference + Workshop Day OR **Conference + Seminar Day** (3 Day Pass)	$5,398 **(Save $200)**	$5,598
Conference Only (2 Day Pass)	$4,299 **(Save $100)**	$4,399

LIMITED PLACES AVAILABLE

CONTENTS

REGISTER NOW